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ABSTRACT
Bone Marrow Microenvironment regulation of BCL6 in
Acute Lymphoblastic Leukemia
William L Slone
Acute lymphoblastic leukemia (ALL) is a hematological malignancy with
approximately 6000 newly diagnosed cases every year. Although ALL is the most
common malignancy in children, it can occur in patients of all ages. Great strides have
been made in the treatment of ALL and remission rates are at all-time highs. However,
relapse rates have remained relatively consistent, and relapse continues to be
correlated with a poor prognosis in patients with ALL. As the site of origin and
progression of ALL, the bone marrow microenvironment (BMM) is important in
regulating tumor cell quiescence and proliferation. Of clinical relevance is the frequency
with which quiescent leukemic cells survive treatment, initiate proliferation, and
contribute to relapse of aggressive disease. In order to design innovative therapies, a
better understanding of the mechanisms by which this regulation occurs is needed.
In order to investigate the mechanisms of BMM mediated protection, and to
develop innovative targeted strategies to disrupt it, in vitro co-culture models remain
critical. Classically, co-culture models that include hematopoietic cells have only
investigated the tumor population as a whole, without regard for potential different
phenotypes based on location of the leukemic cell relative to the adherent BMM cells. In
the first study (Chapters 2 and 3), we investigated whether ALL cells have a variance in
phenotype based on their spatial location within the co-culture. Utilizing bone marrow
stromal cells (BMSC) and human osteoblasts (HOB) as representative elements of the

BMM, in culture with ALL cells, we found that ALL cells form three distinct populations
relative to the BMSC or HOB. ALL tumor cells that migrated beneath the stromal layer,
referred to as phase dim (PD), were characterized by a quiescent and chemotherapy
resistant phenotype. Cell labeling experiments demonstrated that the co-culture model
was dynamic and that ALL cells readily transitioned between populations relative to the
adherent BMM cells. Furthermore, co-culture studies using non-bone marrow derived
adherent layers found that while these co-cultures supported formation of a PD
population, they did not protect ALL cells from chemotherapy exposure. These results
suggest that the increased chemotherapy resistance seen in the PD population is
specific to the crosstalk between ALL cells and the BMSC or HOB. PD ALL cells were
also seen to have an altered metabolic profile, which may contribute to their increased
resistance to chemotherapy. Additionally, we provide a written and video protocol for the
isolation of the three ALL populations from the stromal adherent layers. This extension
of the standard co-culture model will provide researchers a more biologically relevant
method to investigate resistant ALL disease in the context of BMM derived support.
In the final study (Chapter 4), data suggest that microenvironment regulation of
BCL6 in leukemic cells is one factor involved in the transition between the proliferative
and quiescent states of ALL. Observations utilizing Bcr-Abl negative (Ph-), positive
(Ph+) ALL cell lines, and primary patient samples suggest that tumor cell BCL6 protein
expression is decreased due to BMSC and HOB derived signals. Leukemic cells with
decreased BCL6 are characterized by diminished proliferation, G0 accumulation, and
chemotherapy resistance. Conversely, removal of ALL cells from marrow-derived
stroma results in leukemic cells with increased BCL6 expression that are proliferative

and sensitive to chemotherapy. Chemical inhibition or knock-down of BCL6 by shRNA
in ALL cells results in diminished proliferation reminiscent of the quiescent tumor cells
supported by the marrow microenvironment which are chemotherapy resistant and
contribute to relapse of disease. We have developed a unique in vitro recovery model to
test chemotherapy protection of tumor in this unique niche. BMSC/HOB co-cultured
tumor cells are exposed to chemotherapy, and subsequently allowed to recover from
drug imposed insult to determine factors important to tumor survival and repopulation.
While down regulation of leukemic BCL6 leads to a quiescent phenotype, surviving
leukemic cells released from microenvironment constraint have increased BCL6
expression and undergo a period of aggressive proliferation. Since many chemotherapy
regimens require tumor cell proliferation for optimal efficacy, we investigated the
consequences of forced BCL6 expression in leukemic cells when in the protective
microenvironment niche. Data suggest that forcing leukemic cells to express BCL6
when co-cultured with BMSC or HOB sensitizes the tumor to chemotherapy induced cell
death. Furthermore, pre-treatment with drugs that increase BCL6 expression such as
the proteasome inhibitor MG132 or the ATM pathway inhibitor caffeine sensitize
microenvironment protected ALL cells to chemotherapy treatment. These data suggest
that BCL6 is one factor, modulated by microenvironment derived cues that may
contribute to regulation of ALL cell cycle progression and subsequently therapeutic
response.
The overall goal of the studies presented herein was to provide a platform to
investigate treatment resistant ALL that is due to BMM support through the use of our in
vitro co-culture model. Additionally, through the use of this model we are able to

demonstrate mechanistic changes, which can lead to chemotherapy resistance such as
downregulation of BCL6 in ALL subsequent to BMM interaction. These studies provide
mechanistic insight that will contribute to the design of novel treatment strategies that
disrupt protective microenvironment signaling, with a goal of increased chemotherapy
efficacy and less intensive therapies for ALL patients. With a primary goal of reducing
the frequency of relapse, a critical secondary advantage would be the reduction of longterm effects from cytotoxic therapies and potential reduction of treatment induced
secondary malignancies.
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Chapter 1

Literature review and Introduction
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Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia,
is a malignancy that arises from uncontrolled proliferation of abnormal immature
lymphocytes in the absence of differentiation. Typically, this disease initiates and
progresses in the bone marrow. Due to its aggressive or “acute” nature, ALL
progression rapidly leads to damage or loss of normal hematopoiesis and eventual
systemic damage as the immature lymphocytes infiltrate the blood stream and other
organs. It is estimated that there are 6000 new cases of ALL yearly1,2. ALL tends to be
more common in Caucasians and is more prevalent in males than females at a ratio of
3:11,2. ALL most commonly occurs in children with 60% of patients being younger than
21 years old and peak incidence between 2-5 years of age1,2. Remission rates for
childhood ALL approach 90%, however infants 12 months of age or less and adults over
16 as the age have a worse overall prognosis1–3. Modern chemotherapy regimens,
which will be discussed later, have greatly improved patient outcomes; however,
leukemia in general has a long documented history and only in the last century has the
medical and research community began to make strides in the treatment of this
previously consistently fatal disease.
ALL historical perspective
To understand modern ALL treatment regimens, and to consider future
therapeutic strategies, it is important to look at the historical development of early
treatments. While ancient Greek texts describe a disease of the blood which has
characteristics of leukemia as we recognize it today, the first work that lead to leukemia
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being classified as its own clinical entity took place in the early 1800s4,5. Before these
works, many physicians considered what we know today as leukemia to be secondary
to an unknown infection leading to “pus” in the blood. These physicians understood that
infections of the skin resulted in pus production, though they did not yet appreciate that
pus was actually white blood cells4,5. The advent and improvements in microscope
technology allowed for the visualization of the blood and the first accurate descriptions
of white blood cells4. This leap in technology positioned physicians such as Bennett,
Donne and Virchow to piece together that the disease they were observing was a
separate disease of the blood that caused the blood to appear white, which led to the
disease being termed leukemia4,5. In 1865, Lissauer described the first known treatment
for leukemia, which relied on the use of an arsenic solution4. Arsenic solutions were
standard of care to be followed by use of x-rays and early attempts at blood
transfusions4. These treatments continued to be used as treatments for all forms of
leukemia into the 1900s, without any long term benefit to patients, and leukemia
continued to be considered incurable. World Wars I and II brought about research
involving mustard gas derivatives. In the United States, Gilman and Philips observed
that certain nitrogen mustard gas compounds had an impact on lymphoid tissues6. One
of the first mustard gas derivatives shown to have efficacy against hematologic
malignancies was methyl-bis-(β-chloroethyl) amine, following clinical trials at Yale
University4. These findings were follow by the work of Sidney Farber and others, on
anti-folate treatments using the aminopterin7,8. The use of folic acid antagonists, which
are now known to function through disruption of DNA synthesis, provided some of the
first temporary remissions in children9,10. Farber along with Yellapragada Subbarow
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expanded upon these works with the development of methotrexate, which functions as
an antimetabolite resulting in depletion of activated folates needed for DNA synthesis4.
These advances began to improve patient outcomes and lead to some of the first large
scale clinical trials. Of note, in the treatment of ALL are the three cooperative children
patient groups; Acute Leukemia Group A (eventually Children’s Cancer Group [CCG]),
Acute Leukemia Group B (which became Cancer and Leukemia Group B [CALGB]),
Southwest Cancer Chemotherapy Study Group (which evolved into the Southwest
Oncology Group [SWOG])11. These patient groups were used to test the efficacy of the
newly derived anti-folate, methotrexate, and mustard gas derivatives. Also, a critical
discovery of these research studies was that they established the first combination
therapy strategies, which continue to be critical to successful treatment outcomes in
patients10–12. These studies mark a turning point in the treatment of ALL as they
provided the first successful curative treatments. During these clinical group trials,
vincristine was discovered as a possible treatment due to its myelosuppressive effect
and in combination with prednisone and l-asparginase, these agents were added to the
treatment arsenal which lead to increased and lengthened remission rates 11. In the
1960s, prophylactic treatment of the central nervous system (CNS) began, which further
improved outcomes by minimizing the likelihood of relapse of disease that can occur in
this protected anatomical location10,11,13. The use of combination treatments and
prophylactic CNS treatment resulted in ALL cure rates approaching 50% by the 1970s 11.
These successes resulted in further research leading to risk based treatment strategies,
as well as the use of human leukocyte antigen (HLA) matched bone marrow transplant,
further increasing the survival rate for patients with ALL10,11.
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Modern ALL management
On the backs of the fundamental work described above, modern treatment
strategies result in greater than 90% of ALL patients achieving remission1. As was first
discovered with the cooperative children groups of the 1950s, the key to current
treatment has been further optimization of treatment regimens as a majority of today’s
chemotherapy drugs for the treatment of ALL were discovered prior to the 1970s.
Today’s treatments typically consist of three treatment phases which take place over a
2-2.5 year time frame 1,3,14. Treatment phases for ALL are induction, consolidation, and
maintenance. Induction therapy typically consists of treatment with some combination of
vincristine, cytarabine, dexamethasone, prednisone, doxorubicin, daunorubicin, or a
similar anthracycline drug1,3,14. Induction therapy is followed by consolidation, which is
typically retreatment with high doses of induction therapy drugs1,3,14. Maintenance
therapy follows consolidation treatments and typically consists of treatment regimens
containing methotrexate and 6-mercaptopurine. In addition, consolidation treatments
may be combined with other drugs such as vincristine or prednisone, as well as
specifically targeted drugs such as tyrosine kinase inhibitors ( i.e imatinib, dasatinib, and
nilotinib) 1,3,14. Increased awareness and tools for determination of genetic alterations,
and their subsequent use for more informed risk stratification, along with combination
treatment strategies has combined to greatly improve patient outcomes. These
treatment approaches have advanced patient outcomes to all-time highs, with children
having an overall complete remission rate between 90- 96% and adults ranging from 80
to 90% complete remission1–3,14. While these complete remission rates are extremely
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encouraging, relapse of ALL remains a significant issue that often leads to aggressive
disease and poor outcomes.
Relapse of ALL
Modern chemotherapy regimens have greatly increased the number of complete
remission in both children and adults suffering from ALL. Relapse of ALL occurs in 20 to
25% of children and greater than 50% of adult cases of ALL15–19. In both patient
populations, relapse of ALL has a poor prognosis with long term survival of children with
a relapse event ranging from 15 to 50%, and similar or worse outcomes in adults3,14–16.
Relapse of ALL can arise from a number of anatomical locations with the most common
sites being the bone marrow, CNS and testis20. Although these are the most common
sites of ALL relapse, extramedullary relapses have been observed to arise from the iris,
ovaries, and skin21. Though ALL relapse can arise from any of these sites, bone marrow
relapses are the most common and confer the worst prognosis as detailed below.
While genetic mutations such as BCR-Abl or MLL+ rearrangements play a
critical role in the progression and likelihood of relapse22, two fundamental
characteristics of ALL relapses, length of initial remission and site of relapse, are the
most important predictors of long term survival of ALL patients 20,23. Length of remission
has been found to be the most significant predictor of overall survival and is commonly
stratified into three categories early (< 18 months), intermediate (18 to 36 months), and
late relapse (>36 months) with early relapse events having a poor prognosis compared
to longer remission duration23. Work by Nguyen et al. and others has also shown that
the site of relapse is also an indicator of long term survival. As noted previously, the
sites of relapse vary with bone marrow relapses having the worst prognosis compared
6

to relapses arising in the CNS, testis, or other organs20,23. Long term survival of
patients who suffer an early bone marrow relapse has a range from 0-15%, intermediate
medullary relapse ranges from 10 to 40%, late bone marrow range is 14- 50%23. This is
compared to CNS relapses which have a long term survival rate of approximately 51%
and isolated testicular relapses that range from 53 to 84%23. Together these
observations highlight the need for further research to improve outcomes in patients
with relapse by investigating strategies that promote longer remissions. This requires a
mechanistic understanding of the bone marrow microenvironment’s contribution to
resistance and progression of ALL disease.
Bone marrow microenvironment contributions to ALL chemotherapy resistance
To fully understand bone marrow microenvironment (BMM) facilitation of ALL
progression and contribution to chemotherapy resistance, it is important to appreciate
the supportive role the BMM plays in normal hematopoiesis, the “healthy” counterpart of
leukemia, as they respond to many of the same development cues. Neumann and
Bizzozero first postulated that the bone marrow was the site of red blood cell production
in the late 1800s24. Works by Osler elaborated upon Neumann and Bizzozero’s work to
conclude that the bone marrow was an organ with the primary function of producing all
cellular components of the blood24. Today it is understood that the bone marrow is a
complex organ that consists of specific microenvironment niches that function to
regulate hematopoiesis. Furthermore, research continues to determine the functional
role of individual niches within the bone marrow. It is widely accepted that two niches,
the endosteal and the perivascular niche, are critical for normal maintenance and
development of both immature and mature blood cells. However, their specific
7

contributions to white blood cell development is still currently being debated. The
complexity of this anatomical site drives the need for careful consideration of model
development, realizing that while some elements (osteoblasts and stromal cells) may
have overlapping roles, there are likely very specific contributions to steady state
hematopoiesis, and support of leukemic disease as well.
Osteoblastic niche
The endosteal or osteoblastic niche, is localized near the inner bone surface or
endosteum. This niche is comprised of a variety of cell types which include; osteoblasts,
osteoclasts, glial non-myelinating Schwann cells, and regulatory T-cells (T-regs) (Figure
1, 2)25,26. One key component of this niche is osteoblasts, which in coordination with
osteoclasts have been classically described to maintain bone homeostasis27,28. In
addition to the role in bone homeostasis, osteoblasts have been shown in both in vitro
and in vivo studies to regulate hematopoietic stem cells (HSC), as well as progenitor
hematopoietic cell proliferation and differentiation26,29–32. One classic example is
osteoblast mediated Notch signaling which has been shown to regulate HSC
proliferation, self-renewal, and prevention of HSC differentiation31,33. Furthermore,
osteoblast derived growth factors such as granulocyte colony-stimulating factor can be
used to promote HSC expansion in vitro and loss of osteoblasts in vivo results in
decreased abundance of HSCs29,30,34. Additionally, osteoblast production of
Angiopoietin-1 (Ang-1), N-cadherin signaling, and osteopontin appear to promote HSC
quiescence and are hypothesized to maintain the HSC pool preventing stem cell
exhaustion35–37. Due to osteoblast’s propensity to promote hematopoietic cell
phenotypes that promote self-renewal and quiescence, it is of little surprise that
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malignant immature hematopoietic cells also invade this niche to take advantage of
these “protective” signaling cues. For this reason, we and others have interrogated the
signaling that occurs in this site and demonstrated that leukemic cell interaction with
osteoblasts promotes a chemotherapy resistant phenotype38–41. Similar to observations
that have been described for normal HSC, adhesion of ALL cells to ostopontin in the
osteoblastic niche promoted a dormant phenotype and subsequently facilitated
chemotherapy resistance38. Likewise, Saito et al demonstrated in an acute
myelogenous leukemia (AML) mouse model that CD34+CD38− human primary AML
stem cells localized to the endosteum, where they exhibited a chemotherapy resistant
quiescent phenotype42. These observations together illustrate the protective nature of
the osteoblastic niche and are the bases for our investigations into the role this niche
plays in promotion of ALL resistance, which will be further discussed below.
Perivascular niche
Like the osteoblastic niche, there is a wealth of evolving research demonstrating
the impact of the perivascular niche on normal and leukemic physiology. The
perivascular niche is localized at the sinusoidal and arteriole walls, and this niche has
been shown to be made up of C-X-C motif chemokine-12 (CXCL12)-abundant reticular
cells (CAR), endothelial cells, nestin-positive (NES+) mesenchymal stromal cells
(MSCs), leptin receptor positive [LepR(+)] perivascular stromal cells, and nonmyelinating Schwann cells (Figure 1, 2)25,26. The perivascular niche has been described
to promote both proliferative and quiescent HSC phenotypes, and research continues to
delineate the local niches that are responsible for these different states. For example,
non-myelinating Schwann cells that are part of both the osteoblastic niche and the
9

perivascular niche have been reported to activate transforming growth factor-β1 (TGFβ1), which supports HSC quiescence43,44. On the other hand, expression of Notch
ligands Jagged-1, Jagged-2, and Delta-like-1 &4 increased self-renewal of HSCs in
vitro25,45. Even among the same stromal cell population, localization and protein
expression profiles can dramatically alter impacts on HSCs. This was demonstrated by
Kunisaki et al using NES+ MSCs segregated into high nestin phenotype verses those
with lower nestin expression46. Not only did this group show that nestin high and nestin
low MSCs localize to different perivascular niches (arteriolar vs. sinusoidal respectively),
they displayed that the arteriolar nestin high MSC promoted HSC quiescence compared
to the cell cycle active HSCs which localized to areas with nestin low MSCs46. These
examples illustrate the heterogeneity of the “classic” perivascular niche and suggests
that this one niche may, in fact, be two unique niches (arteriolar verses sinusoidal).
More generally this heterogeneous population of stromal cells and MSCs has been
defined as “bone marrow stromal cells” (BMSC). BMSC have been shown to maintain
HSC homeostasis through impacting HSC and progenitor cell proliferation, self-renewal,
differentiation, and homing properties26,47–50. BMSC expression of CXCL12, as well as
signaling lymphocyte attractant molecule (SLAM) proteins, are important to retention of
HSC and progenitor lymphocytes respectively within the perivascular niche 51. BMSC
also produce stem cell factor (SCF), the ligand for the c-kit kinase receptor, which
maintains HSC pools. Correspondingly, deletion of SCF in BMSC resulted in a marked
reduction of HSC numbers52.
In addition to the role BMSCs play in HSC physiology, they also make up niches
that committed progenitor cells occupy and rely on for proliferation and differentiation
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cues. Specifically, work by Ding et al revealed that committed B-lineage progenitors are
dependent on BMSC that reside within the perivascular niche 51. The observation that
committed B-lineage progenitors rely on BSMC in this niche is significant to ALL, as
greater than 80% of ALL cases are malignant pre- or pro B-cells that are lineage
committed but lack full productive rearrangement of immunoglobulin genes 19,53. BMSC
within this niche can even promote or regulate fate of malignant cells as seen in the
case of MLL-AF9 leukemia where BMSC cues can drive the leukemia into either an
AML or B-cell ALL fate54. In addition to differentiation cues, our laboratory and others
have shown that BMSC supported ALL cells are known to exhibit increased
chemotherapy resistance through BMSC induced quiescence and anti-apoptotic
signaling39,40,55–57. These findings were further extended by the identification that in a
multiple patient cohort, resistant ALL cells tended to have upregulation of IL-7 and
CXCR-4 signaling, both of which are known mediators of normal B-cell development
and are signaling pathways driven by BMSC interactions58. Additionally, BMSC
mediated engagement of leukemic Beta1 integrin leads to anti-apoptotic effects through
downregulation of BCL-2 family members such as BIM57,59. Collectively, these studies
highlight the impact the perivascular niche has on normal hematopoiesis and leukemic
proliferation, differentiation, and survival. As BMSCs are key components of this niche,
the studies below utilize human primary bone marrow stromal cells as representative
elements of the perivascular niche to test the impacts on ALL cell chemotherapy
resistance.
Combined, the osteoblastic and perivascular niches of the bone marrow are key
microenvironment sites required for normal hematopoiesis and are a major contributor
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to the leukemia phenotype. As highlighted above and reviewed by others, leukemic cells
communicate intimately with normal niche cues and to some extent rely on these
signals for survival and disease progression60. Reciprocally, the impact of leukemic cells
in the microenvironment has been shown to be detrimental to normal hematopoiesis
with leukemia cells out competing and “hijacking” the normal HSC niches61. Recent
work utilizing an ALL mouse model revealed that cancer-propagating leukemic cells
(CPCs) were able to create small foci CPCs surrounded by BMSC, which resulted in the
leukemic cells being more resistant to chemotherapy at the expense of normal niche
architecture62. Together these studies illustrate the complexity of the BMM and its
important role in leukemic disease, as well as the crosstalk between cells. Greater
understanding of the relationship between the BMM and ALL will allow for targeted
treatment strategies aimed at resistant niche supported cells. In response to this clinical
challenge, our laboratory continues to investigate BMM interactions that support
resistant ALL cells through generation of new in vitro BMM/ALL models and innovative
combination treatment strategies targeting refractory ALL as highlighted below.
Role of BCL6 in ALL chemotherapy resistance
As reviewed above, the BMM plays a critical role in the development of ALL
chemotherapy resistance. In addition to niche cues, intrinsic mutations are known to
promote chemotherapy resistance and correspond with poor outcomes in ALL patients.
Well described translocations such as the Philadelphia chromosome (BCR-ABL)(Ph+)
and the 11q23 rearrangement of the MLL gene are associated with aggressive disease
and increased drug resistance63. Genetic lesions such as deletions or mutations in the
IKZF1 gene or activating mutations in JAK tyrosine kinase have also been linked to drug
12

resistance and high risk ALL disease63. In addition to these well-documented
mutations, BCL6 protein (B-cell CLL/lymphoma 6, zinc finger protein 51) expression has
recently been shown to promote drug resistance in ALL64.
BCL6 or LAZ3 was first characterized in 1993 by two groups as a gene
associated with 3q27 chromosomal translocations in B-cell lymphomas65,66. Soon after
its initial characterization BCL6 was found to also be important in normal germinal
center biology and B-cell development67,68. More recently BCL6 has become recognized
as an important transcription factor in a variety of normal and malignant cell contexts.
BCL6 is a 95 kDa protein that functions as a sequence specific repressor of
transcription69. BCL6 contains three distinct domains, the N-terminal BTB/POZ domain,
a central PEST domain, and 6 C-terminus zinc finger DNA-binding motifs (Figure 3)69.
The N-terminal BTB/POZ domain is critical to BCL6’s function as a transcriptional
repressor, as this domain is responsible for recruitment and binding of histone
deacetylase complexes and co-repressors69. Through this domain BCL6 is able to
directly recruit class I and II histone deacetylases (HDAC)69–71. In addition, BCL6’s BTB
domain is able to recruit and bind multiple corepressors such as; NCOR1, NCOR2,
BCOR, and CTBP1 all of which promote BCL6 function as a transcriptional
repressor69,70,72–76. The POZ portion of this domain can also bind to other zinc finger
proteins such as Miz-1, which was shown by Phan et al to increase the number of DNA
sequences BCL6 could affect through use of the Miz-1 specific zinc finger DNA binding
sites77. The central PEST domain is also responsible for recruitment of co-repressors
and like the BTB domain, it binds to CTBP1, but can also recruit co-repressor
MTA369,76,78. Moreover, this domain regulates stability of BCL6 serving as a site for
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phosphorylation and acetylation69. ATM and MAPK pathway activation can result in
phosphorylation of serine 333 or 343 within the PEST domain leading to BCL6
degradation through the ubiquitin-proteasome pathway79,80. Additionally, FBXO11 has
also been reported to bind BCL6 and subsequently lead to ubiquitination and
proteasomal degradation81. Acetylation of the PEST domain results in a functional
inactivation of BCL6 by preventing recruitment of co-repressors82. The C-terminus zinc
finger DNA-binding motifs are critical to BCL6’s transcriptional activity through direct
binding to sequence specific sites83–86. A few key examples of targeted binding of BCL6
through its zinc finger motifs are repression of p53, TGF-β receptors, STAT family
members, a number of CD markers, as well as, key components of BCR, CD40, MAPK,
and NF-ϰB pathways69. Together these domains allow BCL6 to exert its transcriptional
repression on a large number of targets through direct and indirect DNA binding, as well
as recruitment of co-repressors. This positions BCL6 to regulate critical cellular
programs such as survival, proliferation, and differentiation.
Classically, BCL6 has been studied for its role in germinal center biology and its
impact on diffuse large B-cell lymphoma (DLBCL). In normal B-cell development, BCL6
expression is associated with B-cells of the dark zone of the germinal center87,88.
Fukuda et al showed that nascent pre-germinal center B-cells upregulated BCL6 as a
requirement for migration to the follicular area and initiation of germinal center
formation89. Consistent with the earlier discussion of overlap in bone marrow regulation
of normal hematopoiesis and dysregulation that results in ALL, many critical regulators
have roles in both circumstances. BCL6 expression in the germinal center context
promotes B-cell proliferation and allows for tolerance to DNA damage associated with
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gene rearrangement through repression of p5368,90–92. Additionally, BCL6 modulation is
an important component of plasmacytic differentiation 78,93. Overall, BCL6 regulation and
its functions are essential to normal maturation of B-cells. Also, this likely explains why
disruption to normal BCL6 physiology is a major factor in the lymphogenesis seen in
DLBCL cases. In the case of DLBCL, BCL6 is often constitutively overexpressed due to
translocation or mutations in the BCL6 locus66,94–96. In this context, BCL6 acts in much
the same way it does in normal B-cell development promoting proliferation and
tolerance to DNA damaging stress, thus resulting in B-cell lymphoma94,97–105.
More recently BCL6 has been discovered to play a role in malignancies of
immature B-cells in addition to the role described above for DLBCL, as well as other
forms of hematologic diseases64,106–108. Sarsotti et al. identified a group of B-cell chronic
lymphocytic leukemias with BCL6 mutations and observed that these patients had a
higher risk of disease progression than those without BCL6 mutations109. BCL6 has
also been reported to be critical for leukemic stem cell survival in chronic myeloid
leukemia (CML) through its repression of p53108. Additionally, through generation of a
Ph+ pre- B-cell ALL model, Duy et al. found that BCL6 was also important to ALL
leukemic stem cells64. This group also discovered that BCL6 was upregulated in
response to tyrosine kinase inhibition, and in part promoted survival through TKI
resistance via inhibition of p5364. Collectively, BCL6 is a well-defined factor in the
development of both normal and malignant B-cells that regulates differentiation,
proliferation, and survival.
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Summary
ALL was once a devastating disease with few treatment options and little chance
of survival. Advances in our understanding of this disease, as well as synthesis of a
variety of chemotherapy agents allowed for the first breakthroughs in the treatment of
ALL. Moreover, modern combination treatments have resulted in some of the highest
response rates seen in all forms of cancer. However, relapse of disease remains a
persistent problem in the long term survival of patients with ALL and relapse events
commonly still result in aggressive and drug resistant disease leading to poor outcomes.
One major contributor to relapse of disease is the frequency with which ALL cells persist
in the bone marrow niche and contributes to refractory disease that is inevitably
aggressive. This clinical challenge provides the rational for the projects described
herein, in which our laboratory aims to establish an efficient and accurate in vitro, preclinical representation of the most drug resistant ALL populations supported through
BMM interactions. In the manuscript Slone and Moses et al., we provide instruction and
representative results of our in vitro model of ALL and the BMM, in which we establish
and recover a chemotherapy resistant ALL population (Chapter 2)40. This is followed by
our report in which the BMM supported in vitro ALL chemotherapy resistant population
is further characterized (Chapter 3)39. In addition to the promotion of chemotherapy
resistance through BMM interaction, upregulation of the proto-onco gene BCL6 is
known to support ALL drug resistance64. However, a major gap in the field is an
understanding of how the BMM influences ALL levels of BCL6. This gap, as well as
potential interventions surrounding BMM modulation of ALL BCL6 abundance, is
discussed in Chapter 4. Collectively, the goal of this project is to provide a better in vitro
16

platform in which to test hypotheses centered on ALL and BMM interactions that lead to
resistant disease. Additionally, through use of these models, we aim to better
understand the impact of the BMM on ALL BCL6 levels and use this information to
further progress current chemotherapy regimens, so that refractory disease may be
reduced and relapse of ALL prevented. While preventing relapse is the unifying goal of
these studies, observations that contribute to reduced need for intense and repeated
chemotherapy exposure in children is also an important consideration given the long
term consequences including the generation of secondary malignancies. Together,
these concerns underpin the following studies.
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Figures

Figure 1. Mechanisms involved in HSCs and LICs maintenance in osteoblastic and
vascular niches.
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Figure 2. The adult bone marrow HSC niche.
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Figure 3. Schematic representation of BCL6 illustrating its key domains and binding
partners.

Adapted from: Basso K, Dalla-Favera R. Roles of BCL6 in normal and transformed
germinal center B cells. Immunol. Rev. 2012;247(1):172–183.
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SHORT ABSTRACT: The current report summarizes a protocol that can be utilized to
model the influence of the bone marrow microenvironment niche on leukemic cells with
emphasis placed on enrichment of the most chemoresistant subpopulation.

LONG ABSTRACT: It is well established that the bone marrow microenvironment
provides a unique site of sanctuary for hematopoietic diseases that both initiate and
progress in this site. The model presented in the current report utilizes human primary
bone marrow stromal cells and osteoblasts as two representative cell types from the
marrow niche that influence tumor cell phenotype. The in vitro co-culture conditions
described for human leukemic cells with these primary niche components support the
generation of a chemoresistant subpopulation of tumor cells that can be efficiently
recovered from culture for analysis by diverse techniques. A strict feeding schedule to
prevent nutrient fluxes followed by gel type 10 cross-linked dextran (G10) particles
recovery of the population of tumor cells that have migrated beneath the adherent bone
marrow stromal cells (BMSC) or osteoblasts (OB) generating a “phase dim” (PD)
population of tumor cells, provides a consistent source of purified therapy resistant
leukemic cells. This clinically relevant population of tumor cells can be evaluated by
standard methods to investigate apoptotic, metabolic, and cell cycle regulatory
pathways as well as providing a more rigorous target in which to test novel therapeutic
strategies prior to pre-clinical investigations targeted at minimal residual disease.
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INTRODUCTION: The overall goal of the method described is to provide an efficient,
cost-effective in vitro approach that supports investigation of the mechanisms that
underlie bone marrow supported survival of leukemic cells during chemotherapy
exposure. It is well documented that surviving residual tumor cells that persist after
treatment contribute to relapse of disease that is often more aggressive than that at
diagnosis and is often less effectively treated1–8. Models that include leukemic cells in
isolation, such as those limited to culture of cells in media alone, for testing of
therapeutic approaches do not factor in these critical signals, or the heterogeneity of
disease that occurs in response to availability of niche derived cues in which tumor cell
subpopulations with very specific interactions with niche cells derive enhanced
protection. Standard 2D co-culture models that co-culture bone marrow derived stromal
cells and leukemic cells have somewhat addressed the contribution of the marrow niche
and have shown that interaction with bone marrow microenvironment cells increases
their resistance to chemotherapy and alters their growth characteristics9–14. These
models however often fail to recapitulate long term survival of tumor cells and do not
accurately inform the outcomes associated with the most resistant leukemic cell
populations that contribute to MRD. In vivo models remain critical and define the “gold
standard” for investigation of innovative therapies prior to clinical trials but they are often
challenged by the time and cost required to test hypotheses related to resistant tumors
and relapse of disease. As such, development of more informative 2D models would be
of benefit for pilot investigations to better inform the design of subsequent murine based
pre-clinical design.
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The 2D in vitro model presented in this report lacks the complexity of the true in vivo
microenvironment, but provides a cost effective and reproducible means to interrogate
tumor interactions with the microenvironment that lends itself specifically to enrichment
of the chemoresistant subpopulation of tumor cells. This distinction is valuable as
evaluation of the entire population of tumor cells may mask the phenotype of a minor
group of therapy resistant tumor cells that comprise the most important target. An
additional advantage is the scalability of the model to fit the analysis of interest. Bulk
cultures can be established for those analyses requiring significant recovery of tumor
cells, while small scale co-cultures in multi-well plates can be utilized for PCR based
analysis or microscopy based evaluations.

Based on this need we developed an in vitro model to address the heterogeneity of
disease that is characteristic of B-lineage acute lymphoblastic leukemia (ALL). We
demonstrate that ALL cells, which share many characteristics in common with their
healthy counterparts, localize to distinct compartments of BMSC or OB co-culture.
Three populations of tumor cells are generated that have distinct phenotypes that are
valuable for investigation of therapeutic response. Specifically, we demonstrate that
(ALL) cells recovered from the “phase dim” (PD) population of co-culture are
consistently refractory to therapy with survival that approximates tumor cells that have
not been exposed to cytotoxic agents. These ALL cells, from either established cell lines
or primary patient samples, migrate beneath adherent stromal cells or osteoblast layers
but can be captured following trypsinization of cultures and separation of cell types by
utilization of gel type 10 cross-linked dextran (G10) particle columns15.

34

Here we present a setup of a 2D co-culture that can be employed to model interactions
between bone marrow microenvironment stromal cells (BMSC/OB) and leukemic cells.
Of particular importance is the observation that leukemic cells form three spatial
subpopulations relative to the stromal cell monolayer and that the PD population
represents a chemotherapy resistant tumor population due to its interaction with the
BMSC or OB. Furthermore, we demonstrate how to effectively isolate the leukemic cell
populations by G10 columns. Of note, we have found that isolation of these
subpopulations allows for downstream analysis of the most resistant PD population to
determine potential modes of resistance that are conferred to these cells due to their
interaction with the bone marrow microenvironment stromal cells or osteoblasts.
Techniques that we have utilized downstream of this co-culture and isolation model
include flow cytometric evaluation, proteomic analysis and targeted protein expression
evaluation as well as more recently developed laser ablation electrospray ionization
(LAESI) and Seahorse analysis to evaluate metabolic profiles. Through use of this
model in combination with the techniques above we have found that the PD population
of leukemic cells has a chemotherapy resistant phenotype that is unique when
compared to leukemic cells cultured in media alone or those recovered from the other
subpopulations in the same co-culture. As such, this model lends itself to more rigorous
evaluation to test strategies targeting the most chemotherapy resistant leukemic cells
which derive their resistant phenotype through interaction with the bone marrow
microenvironment.
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Protocol:
1. Advanced preparation
1.1) Preparing G10 particles.
1.1.1) Prepare G10 slurry by adding 50 ml 1x PBS to 10g G10 particles. Mix by
inversion and allow G10 to settle out of phosphate buffered saline (PBS) at 4ºC
overnight.
1.1.2) The day of G10 column separation, aspirate PBS from settled G10 particles
and add 50 ml fresh PBS. Mix by inversion. Repeat twice, adding 50 ml fresh PBS to
settled G10 particles and store at 4ºC until ready to use.
1.2) Culturing BMSC and OB.
1.2.1) Both BMSC or OB are maintained at 37 ºC in 6% CO2 and grown on 10 cm
tissue culture plates until 90% confluency is reached.
1.2.2) BMSC or OB cells are trypsinized and split 1:2 onto new 10 cm plates. The
cells are grown to these standards until needed for leukemic co-culturing.
2. Establishing and maintaining co-culture
2.1) Add 5-20 x106 leukemic cells in 10 ml of tumor specific culture media onto an
80-90% confluent BMSC or OB plate.
NOTE: Our lab maintains co-cultures at 37 ºC in 5% O2 to better recapitulate the
bone marrow microenvironment which has been shown to range from 1 to 7% 16–18 .
However, maintaining co-cultures at this oxygen tension is not critical for the
establishment of the three leukemic subpopulations and is at the discretion of the
lab.
2.2) Every 4th day remove all but 1 ml of media (including leukemic cells in
suspension) and replace with 9 ml fresh leukemic culture media.
NOTE: When removing 9 ml of media from plate, be careful not to disturb the BMSC
or OB adherent layer. Remove media by tilting plate to the side and aspirate media
in the corner of the plate. Additionally, when adding fresh media, be sure to add drop
wise in the corner of the plate against the sidewall to ensure minimal disruption of
the BMSC or OB adherent layer.
2.3) After the 12th day of co-culture, rinse leukemic cells from BMSC or OB layer by
pipetting culture media from dish up and down gently over the dish approximately 5
to 10 times and then collect in 15 ml conical tube. Reseed onto new 80-90%
confluent BMSC or OB plate as described in step 2.1.
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NOTE: The gentle rinsing of the co-culture as described in step 2.3 will remove S
and PB leukemic cells without disrupting the BMSC or OB monolayer. This allows
only tumor cells to be transferred to the next co-culture plate. This 12 day cycle can
be repeated as many times as needed based on user needs.
3. Preparing G10 bead columns
NOTE: If sterile downstream analysis or culturing is required following G10 column
separation the following steps should be carried out using sterile technique and G10
columns should be setup in a sterile biological hood.
3.1) Pre-warm cell culture media to 37ºC in water bath (~30 ml per column).
3.2) Using a 10 ml disposable syringe, remove and discard plunger.
3.3) Add glass wool to syringe.
3.3.1) Using tweezers, pull apart glass wool into thin loose strands. Add multiple
layers of lightly packed glass wool to the syringe until 2/3 of the syringe is filled with
glass wool.
NOTE: The glass wool is crucial to prevent loose G10 particles from contaminating
the leukemic cell collection. Make sure glass wool is packed enough to support the
G10 particles, but not too densely packed to block media flow through the column.
3.4) Attach 1-way stopcock to the tip of the syringe in the closed position.
3.5) Clamp syringe column to ring stand high enough so a 50 ml conical tube
(collection tube) can be placed underneath stopcock. Place collection tube under
syringe column.
3.6) Using a 10 ml pipette add, drop-wise, G10 particles resuspended in PBS to the
column on top of the glass wool. Continue adding G10 particles until a ~2 ml pellet
(as measured by graduations on syringe) of G10 particles forms on top of the glass
wool.
3.7) Equilibrate the G10 column with pre-warmed media.
3.7.1) Add 2 ml of pre-warmed media to column. Open stopcock valve slowly so that
media flows out of the column drop-wise.
3.7.2) Repeat step 3.7.1 until a total of 10 ml of pre-warmed media have been ran
across the column.
NOTE: If G10 particles are seen in the flow through in the collection tube, either 1)
add more G10 particles to maintain ~2 ml pellet making sure no additional G10
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particles escape from the column or 2) replace column with an unused one and
repeat steps 3.5-3.7.1.
3.7.4) Once the pre-warmed media drains from the column, close the stopcock and
discard collection tube with flow through.
3.7.5) Add new collection tube under column. Column is ready to be loaded with
media + cell mixture.
NOTE: Columns should be used immediately and not allowed to dry.
4. Separating 3 subpopulations within co-culture
4.1) Collection of suspension (S) tumor subpopulation.
4.1.1) Aspirate media from co-culture plate with pipette and gently reapply the same
media to rinse the plate and collect media containing leukemic cells in a 15 ml
conical tube. The leukemic cells collected are the S subpopulation.
4.2) Collection of Phase Bright (PB) tumor subpopulation.
4.2.1) Add 10 ml fresh media back onto co-culture plate. Rinse vigorously by
pipetting added media up and down approximately 5 times to remove adherent
leukemic cells but not hard enough to dislodge adherent BMSC/OB component.
4.2.2) Aspirate with pipette and collect media in a 15 ml conical tube. The collected
cells are the PB subpopulation.
4.3) Collection of Phase Dim (PD) tumor subpopulation.
4.3.1) Rinse plate with 1 ml PBS to remove remaining media. Trypsinize co-culture
plate with 3 ml trypsin and place into 37ºC incubator for 5 min.
4.3.2) Remove plate out of incubator and gently tap sides of the plate to dislodge
adherent BMSC/OB.
4.3.3) Add 1 ml fetal bovine serum (FBS) and pipette up and down 3-5 times to
break apart large cell aggregates.
4.3.4) Collect media with cells in a 15 ml conical tube. These cells are the unpurified
PD subpopulation with BMSC/OB as well.
4.4) Centrifuge 3 isolated subpopulations at 400x g for 7 min. Aspirate and discard
supernatant then individually resuspend pellets in 1 ml pre-warmed media. Cells are
ready to be loaded onto a G10 column.
5. Loading co-culture cells onto G10 column
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NOTE: Make sure stopcock is completely closed before adding media containing
cells to G10 column. Also, each subpopulation must be ran over a separate G10
column so not to introduce any bias between populations in downstream analysis.

5.1) Using a 1000 µl pipette, add 1 ml of each cell subpopulation in pre-warmed
media to a separate G10 column drop-wise. The media containing the cells should
remain on top or within G10 pellet.
5.2) Allow cells to incubate on G10 pellet for 20 min at RT.
NOTE: Stopcock remains closed for duration of incubation.
6. Collecting leukemic cells from G10 column
6.1) Add 1-3 ml pre-warmed media to each G10 column.
6.2) Open stopcock valve and allow media to slowly exit the column drop-wise.
NOTE: It is crucial to maintain a slow flow rate from the column or the G10 pellet
containing BMSC/OB can wash out of the column and contaminate the isolated
leukemic cells.
6.3) Continue to add pre-warmed media in small increments (1-2 ml) to G10 column
until a total of 15 to 20 ml has run through column and has been collected. Close
stopcock valve and cap collection tube.
NOTE: If a G10 particle pellet is seen at the bottom of collection tube, gently remove
media from the tube leaving G10 particle pellet undisturbed and transfer to new
tube.
6.4) Centrifuge collected media at 400x g for 7 min at RT.
6.5) Remove supernatant and resuspend cell pellet in buffer appropriate for
downstream application.
6.6) Cells are now a pure population of leukemic cells free of BMSC or OB
contamination and are ready to be applied to downstream applications at user
discretion.
NOTE: Leukemic cell viability should remain unchanged when passing cells through
G10 columns.
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Representative results: Successful setup and culture of this co-culture model will
result in the establishment of 3 subpopulations of leukemic cells relative to the adherent
BMSC or OB monolayer. Figure 1 shows how ALL cells seeded into a BMSC
monolayer initially appear as only a single population of suspended leukemic cells. Over
the course of 4 days leukemic cells interact with the BMSC to form 3 spatial
subpopulations of leukemic cells (suspended (S), phase bright (PB), and phase dim
(PD)). While the 3 subpopulations of tumor cells can commonly be seen after 24 hours
of co-culture with BMSC or OB we co-culture the cells for 4 days to allow the full
dynamics and interactions between the leukemic cells and BMSC/OB cells to take place
before any manipulation or experimentation takes place (Figure 1). Also, note that we
maintain the co-cultures at an oxygen tension of 5% to recapitulate bone marrow
physiology, which has been reported to range from 1-7%16–18.
A vast majority of downstream analysis requires the separation of the leukemic cells
from the BMSC or OB. To achieve this we use G10 columns to harvest a pure
population of leukemic cells (Figure 2A). Following trypsinization of BMSC and PD REH
cells a mixed population is seen by two distinct forward/side populations by flow
cytometry (Figure 2B, top panel). Following G10 separation a pure population of only
REH ALL cells is recovered, which was confirmed by forward/side scatter flow
cytometry (Figure2B, bottom panel).
Use of this co-culture model and the ability to isolate leukemic cells from 3
subpopulations when in co-culture with BMSC or OB allows for interrogation of leukemic
cell phenotype with relation to its spatial location relative to the adherent BMSC or OB
monolayer. Of particular interest, is that ALL cells recovered from the PD population of a
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BMSC or OB co-culture have little to no cell death following exposure to cytotoxic
chemotherapy (Figure 3 A,B).
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Discussion: Minimal residual disease (MRD) which contributes to relapse of disease
continues to be a major clinical challenge in the treatment of aggressive refractory ALL,
as well as, a host of other hematological malignancies. The bone marrow
microenvironment is the most common site of relapse in ALL3,8. As such, models that
model the bone marrow microenvironment are vital tools to test hypotheses related to
leukemic tumor cell survival and maintenance of MRD during chemotherapy exposure.
While mouse models define the gold standard for testing questions related to drug
efficacy, 2D co-culture continues to be a cost effective methodology for testing
hypotheses and drug strategies related to bone morrow microenvironment support of
leukemic cell survival. Many groups have shown that co-culture of leukemic cells with
BMSC or OB provides a survival advantage when challenged with chemotherapy
agents9,10,12–14,19–21. Work modeling normal immature CD34+ hematopoietic cells in coculture with mesenchymal stem cells (MSC) revealed that hematopoietic cells will
interact with the adherent monolayer of MSCs to form three distinct spatial populations
of hematopoietic cells22,23. Proliferation and differentiation of the CD34+ cells was
effected relative to their location within the co-culture22. We have expanded on this
observation to test questions related to bone marrow microenvironment stromal cell
support of a resistant population of tumor cells within a 2D co-culture and its isolation for
downstream analysis.
Unlike standard 2D co-culture models which typically sample leukemic cells by removal
of the suspended tumor, our model shows that co-culture represents a more dynamic
interaction in which leukemic cells in co-culture with BMSC or OB form three
subpopulations relative to the BMSC or OB monolayer (Figure 1). The tumor
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subpopulations that form are suspended (S) tumor, which is freely floating in the media;
phase bright (PB) that is adhered to the surface of the BMSC or OB; and the phase dim
(PD) which have buried beneath the BMSC or OB monolayer (Figure 1). In this model,
we found that a strict feeding and reseeding schedule is important to achieve consistent
results in a co-culture model and therefore we feed the co-cultures at 4 day intervals
and transfer tumor to new BMSC or OB monolayers every 12 days. This may require
modification for alternative tumor types as needed. The number of tumor cells that will
migrate below the BMSC or OB to form the PD population may vary between different
leukemic cells. This can be a limitation of the model, when the number of PD tumor cells
are low making it difficult to collect enough cells for downstream analysis. In some
cases this problem can be overcome by establishing replicate co-cultures to allow for
pooling of the three individual subpopulations.
As this model relies on tumor cell interaction with the BMSC or OB it is important to
have an effective method to remove stromal cell contamination to address specific
biology of the leukemic cells. To accomplish this separation of tumor cells from stroma
we use G10 columns. Proper setup and use of these columns is crucial for isolation of
pure tumor populations for downstream analysis. As highlighted in Figure 2B, proper
execution of the G10 column separation results in recovery of tumor cells at greater
than 99% purity. This allows for downstream analysis of the leukemic cells without
complication of interpretation of results that would result from stromal cell
contamination. It is important to note that all leukemic cell types whether cell lines or
primary patient samples will vary slightly in their ability to pass through the G10
columns. Before use in large scale experiments users should determine the number of
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leukemic cells they must input to recover the desired amount needed for their specific
downstream needs. In addition, the amount of wash media ran over the G10 column
post incubation can be increased to try and increase the number of cells recovered.
Care should be taken to insure that the additional washes do not cause stromal cell
contamination which can be determined post wash by cell counts or flow cytometry
analysis of flow through.
In establishing this model, we observed that leukemic cells recovered from the PD
population have increased viability compared to leukemic cells grown in media alone, as
well as to those recovered from the S or PB populations in the same co-culture when
exposed to cytotoxic chemotherapy (Figure 3 a-b). This is significant because it
represents a population of leukemic cells in vitro that derive pronounced protection from
chemotherapy. This provides a useful tool to test treatment strategies aimed at targeting
the most resistant tumor population, which is supported by the bone marrow
microenvironment. Furthermore, because these leukemic cells are so well protected by
the BMSC or OB co-culture it is amenable to in vitro combination treatment strategies,
that in media alone or standard co-culture models would appear to or would completely
kill the tumor which is not always representative of effects seen in resistant
microenvironment supported leukemic populations.
Finally, we believe that use of this model can provide valuable insight into the
interactions between BMSC/OB, and leukemic cells that are responsible for resistance
to chemotherapy treatment, lead to MRD, and subsequently relapse. This model
provides an in vitro platform to design experiments which will better inform downstream
pre-clinical models. Though we show use of this model to test interactions between
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bone marrow stromal cells and ALL derived leukemic cells, we are hopeful that future
directions and applications of this model will be useful in a variety of malignancies in
which the bone marrow microenvironment provides a site of sanctuary for tumors during
chemotherapeutic intervention.
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Figure legends
Figure 1: ALL cells in co-culture with BMSC or OB form three spatial populations.
Our lab uses an in vitro co-culture system to model leukemic cell interactions with bone
marrow microenvironment derived stromal cells (BMSC or OB). To establish co-culture,
leukemic cells (Red) are seeded onto an 80-90% confluent monolayer of BMSC or OB
(Blue), which is denoted as ‘Time 0’. Co-cultures are maintained at 37ºC at 5% oxygen
to approximate conditions of the bone marrow microenvironment. Leukemic cells will
begin to form 3 subpopulations as early as 24 hours, but to allow for complete
interactions to form we allow co-cultures 4 days to establish before utilizing leukemic
cells for experiments. By day 4 (right panels), three subpopulations of leukemic cells will
form in relation to the adherent monolayer. The schematic (top right) and the phase
contrast microscopy (bottom right) show the suspended (S) leukemic cells freely floating
in the media; phase bright (PB) leukemic cells which are adhered to the surface of the
BMSC or OB monolayer; and the phase dim (PD) leukemic cells that have migrated
beneath the BMSC or OB monolayer. Scale bar represents 10 microns.
Figure 2: Use of G10 columns allows for separation of ALL cells from BMSC/OB.
(A) Demonstration of the process of using a G10 column to separate ALL cells from
BMSC/OB co-culture to achieve a pure population of tumor cells for downstream
analysis. From left to right, a mixture of ALL cells and BMSC/OB cells is added to the
top of the G10 column; (Center) cell mixture will settle in the G10 slurry and should be
incubated at RT for 20 min (Note: Stopcock is in the closed position throughout
first two steps); (right) leukemic cells are recovered by opening the stopcock and
rinsing column with pre-warmed media. (B) Top panel shows before G10 separation
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that there is a mixed population of cells containing BMSC (blue gate) and REH ALL
cells (red gate) by evaluating forward (FSC) and side scatter (SSC) analysis. Bottom
panel, following G10 separation only the pure population of REH ALL cells (red gate)
remain with less than 1% stromal cell contamination (blue gate).
Figure 3: PD leukemic cells have increased resistance to chemotherapy
exposure. SD-1 leukemic cells recovered from the PD population of a BMSC co-culture
(A) do not display reduced viability following a 4 day exposure to Ara-C [1µM], MTX
[50µM], or VCR [25µM], similar to untreated controls (note that a second dose of Ara-C
added at 48 hours to account for any drug loss due to stability) . Leukemic cells from the
media alone, S, and PB populations have significantly reduced viability as determined
by trypan blue exclusion. SD-1 leukemic cells co-cultured with OB cells display similar
trends in viability (B). Results are expressed as mean ± SEM. (*) denotes p < 0.05,
unpaired t-test relative to untreated controls.
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Figures

Figure 1: ALL cells in co-culture with BMSC or OB form three spatial populations.
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Figure 2: Use of G10 columns allows for separation of ALL cells from BMSC/OB.
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Figure 3: PD leukemic cells have increased resistance to chemotherapy exposure.
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Abstract
Acute lymphoblastic leukemia (ALL) treatment regimens have dramatically improved the
survival of ALL patients. However, chemoresistant minimal residual disease (MRD) that
persists following cessation of therapy contributes to aggressive relapse. The bone
marrow microenvironment (BMM) is an established “site of sanctuary” for ALL as well as
myeloid lineage hematopoietic disease, with signals in this unique anatomical location
contributing to drug resistance. Several models have been developed to recapitulate the
interactions between the BMM and ALL cells. However, many in vitro models fail to
accurately reflect the level of protection afforded to the most resistant sub-set of
leukemic cells during co-culture with BMM elements. Pre-clinical in vivo models have
advantages, but can be costly, and are often not fully informed by optimal in vitro
studies. In the current report we describe an innovative extension of 2D co-culture
wherein ALL cells uniquely interact with bone marrow derived stromal cells. Tumor cells
in this model bury beneath primary human bone marrow derived stromal cells or
osteoblasts, termed “phase dim” (PD) ALL, and exhibit a unique phenotype
characterized by altered metabolism, distinct protein expression profiles, increased
quiescence, and pronounced chemotherapy resistance. Investigation focused on the PD
subpopulation may more efficiently inform pre-clinical design and investigation of MRD
and relapse that arises from BMM supported leukemic tumor cells.
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Introduction
The bone marrow microenvironment (BMM) is a well-established “site of sanctuary” in a
host of malignancies, with the most common being of hematopoietic origin[1–8]. In
leukemia, the BMM serves as the site of initiation and progression of disease. The BMM
is also the most common site of relapse, where leukemic cells respond to signals that
are critical for the support of “healthy” steady-state hematopoiesis[2,9,10]. Quiescence,
metabolism, and survival pathways are all influenced by the BMM and are pathways
known to be co-opted by leukemic cells in the marrow niche to promote treatment
resistance[5,7,11]. Studies from many laboratories have furthered our understanding of
the interplay between leukemic cells and the BMM, however, relapse of disease
continues to be a clinical challenge.
A number of models have been employed to recapitulate the interactions between the
bone marrow niche and leukemic cells. In vivo murine models have provided insight and
have become standard pre-clinical models in which to test novel therapeutic
strategies[12–14]. While in vivo models define the gold standard they are labor
intensive, time consuming, and costly to test hypotheses related to relapse of disease.
Also, while the BMM can be effectively imaged during disease progression or treatment
response, sequential sampling of tumor recovered from the niche is only achievable
upon termination of experiments, resulting in evaluation of snapshots in time. Often,
ongoing analyses are limited to peripheral circulating tumor that does not reflect the
most treatment-resistant subpopulation of interest. Standard 2D in vitro models, while
lacking the complexity of the in vivo microenvironment, provide an alternative means to
interrogate tumor interactions with the microenvironment. Several groups have
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demonstrated that 2D co-culture with primary human bone marrow stromal cells
(BMSC) and osteoblasts (HOB) protect human leukemic cells from chemotherapy
induced death[2,6,8,11,15]. However, standard in vitro models lack the ability to predict
long term survival of sub-sets of resistant leukemic cells, and as a result, are not ideal
for evaluation of mechanisms that underlie MRD.
Studies including co-culture of healthy hematopoietic stem cells with mesenchymal
stromal cells (MSC) revealed that co-culture models exhibit a more dynamic nature than
was previously appreciated. Hematopoietic cells interacted with MSCs in three distinct
spatial compartments[16]. The subpopulations included uniquely identifiable suspended
(S), phase bright (PB), or phase dim (PD) tumor cells when evaluated by light
microscopy. Differences in the hematopoietic stem cell phenotype correlated with
location of the hematopoietic cell relative to adherent MSC. Of particular relevance to
the current study was the observation that the “phase dim” (PD) population of
hematopoietic cells that buried beneath the MSC monolayer was immature and
quiescent, two characteristics that have been associated with chemotherapy
resistance[16,17]. In addition, it has previously been described that tumor cells closely
associated with BMSC or HOB niches in vivo are more resistant to chemotherapyinduced apoptosis[11,18].
Based on previous works we sought to determine whether B- lineage acute
lymphoblastic leukemia (ALL) cells, which share many common characteristics with
their healthy pre- and pro-B cell counterparts, would localize to distinct compartments of
BMSC or HOB co-culture resulting in distinct subpopulations for investigation of
therapeutic resistance. We demonstrate that ALL cells recovered from the PD
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population of co-culture are phenotypically distinct, and exhibit many characteristics of
refractory disease described in vivo. PD derived tumor cells are resistant to therapy with
survival that approximates tumor cells that have not been exposed to cytotoxic agents.
When compared to the other subpopulations recovered from the same co-culture, PD
leukemic cells, in addition to their marked survival during chemotherapy exposure, were
characterized by increased quiescence and elevated glycolytic activity. Our
observations suggest that a biologically relevant model of minimal residual disease can
be utilized in vitro that benefits from the inclusion of relevant human derived BMM
constituents and targeted evaluation of the most resistant component of ALL. The PD
leukemic cells in this model lend themselves to more rigorous drug screening than can
be achieved when total leukemic populations are evaluated. Importantly, this novel
approach of focus on the PD tumor cells may also more efficiently inform pre-clinical
design to investigate MRD and relapse, with specific consideration of resistant
subpopulations supported by the BMM.
Materials and Methods
Cell lines and culture conditions
Bcr;Abl (Ph+) lymphoblastic cell lines Tom-1 (DSMZ-ACC 578), Nalm-27 (Fujisaki
Cancer Center), Nalm-30 (Fujisaki Cancer Center), and Sup-B15 (ATCC-CRL-1929)
and (Ph-) REH (ATCC-CRL-8286) and Nalm-6 (ATCC-CRL-1567) were utilized. Deidentified primary bone marrow stromal cells (BMSC) were provided by the Mary Babb
Randolph Cancer Center (MBRCC) Biospecimen Processing Core and the West
Virginia University Department of Pathology Tissue Bank. BMSC cultures were
established as previously described[19]. Human osteoblasts (HOB) were purchased
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(PromoCell, Heidelberg, Germany), and cultured according to the supplier’s
recommendations. Co-cultures were established by seeding leukemic cells onto 80-90%
confluent BMSC or HOB monolayers. Cultures were fed every 4 days and tumor cells
collected for inclusion in experiments with remaining leukemic cells moved to new
primary BMSC or HOB adherent layers every 12 days. Cultures were maintained in 5%
O2 to model normal bone marrow oxygen tension, reported to range from 1-7%[20–22].
Suspended (S) leukemic cells floating freely in the media were removed by gentle
pipetting. Phase bright (PB) tumor cells, that were loosely adherent to the top of BMSC
or HOB, were harvested by vigorous pipetting. Phase dim (PD) leukemic cells that were
buried firmly beneath adherent BMSC or HOB were recovered by trypsinization of the
adherent layer and PD tumor. The S, PB, and PD tumor populations were separated
from BMSC/HOB by size exclusion with G10 Sephadex (Sigma, St Louis, MO, USA)
column separation[23,24].
Microscopy
Phase contrast images were acquired using a Leica DMIL LED microscope and
processed by Leica application suite version 4.0 software (Buffalo Grove, IL, USA).
Confocal images were acquired using an upright LSM 510 Zeiss microscope and
processed using Zen2009 software (Thornwood, NY, USA). Fluorescence intensity for
image acquisition was only altered when fluorescence intensities were not compared
between samples.
Subpopulation tracking
The three ALL subpopulations were isolated from co-culture as described above. Each
subpopulation (S, PB and PD) was individually stained with CellTracker™ Green,
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CellTracker™ Violet, or CellTracker™ Deep Red (Life Technologies, Grand Island, NY,
USA) following the manufacturer’s protocol. An equal number of cells from each
population was combined and cultured on coverslips with confluent BMSC or HOB for 1,
4 and 48 hours. Coverslips were extensively washed with PBS to remove S and PB
subpopulations, fixed with 4% paraformaldehyde, and stained with phalloidin-TRITC
(Sigma). Slides were mounted with Prolong® Gold anti-fade (Life Technologies), and
evaluated by confocal microscopy.
Chemotherapeutic agents
Cytarabine (Ara-C) (Selleckchem, Houston, TX, USA; Cat # S1648), Methotrexate
(MTX) (Selleckchem, Cat # S1210) and Vincristine (VCR) (Selleckchem, Cat # S1241)
were stored per manufacturer recommendations, and diluted in base media immediately
prior to use. Experimental concentrations of Ara-C [1 µM], MTX [50 µM], or VCR [25
µM] were used to approximate clinically relevant doses in ALL[25–29].
Evaluation of leukemic cell viability
ALL cells were cultured in media alone, or co-cultured with BMSC or HOB for 4 days to
establish S, PB, and PD tumor populations. At day 4, cultures were provided fresh
media and exposed to Ara-C, MTX, or VCR for 4 days. Cells treated with Ara-C were
exposed to a second dose at 48 hours. Viability was evaluated by trypan blue exclusion
in triplicate samples.
Annexin V/PI staining
Cell culture and chemotherapy exposure were completed as described above.
Following drug exposure ALL cells were stained using an Annexin V (FITC)/ propidium
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iodide (PI) apoptosis detection kit (Trevigen, Gaithersburg, MD, USA; Cat # 4830-01-K)
according to the recommended protocol of the manufacturer. Collection and analysis
were performed in triplicate using the LSRFortessa (Becton Dickenson, San Jose, CA,
USA).
Co-culture of tumor cells with non-bone marrow derived adherent cells
ALL cells were cultured in media alone, or co-cultured with sheep choroid plexus
epithelial cells (SCP) (ATCC-CRL-1700), 3T3 mouse embryonic fibroblasts (3T3)
(ATCC-CRL-1658), mouse embryonic fibroblasts (MEF) (ATCC-CRL-2991), human
embryonic kidney cells (293T) (ATCC-CRL-3216), or HT-1080 human fibrosarcoma
derived cells (HT) (ATCC-CCL-121). Leukemic cells were cultured with adherent layers
for 4 days to establish S, PB, and PD tumor populations comparable to those
established with human BMSC/HOB. At day 4, cultures were exposed to Ara-C and
evaluated for viability by trypan blue exclusion in triplicate as described above.
In vitro relapse model
ALL cells were grown in co-culture with BMSC or HOB for 4 days. At day 4, cultures
were provided fresh media and exposed to Ara-C for 72 hours. Following Ara-C
exposure, S and PB ALL cell subpopulations were harvested as previously described
and viability enumerated by trypan blue exclusion. Co-cultures, in which PD tumor cells
remained buried beneath adherent BMSC/HOB, were rinsed to remove residual Ara-C
and subsequently repopulation was monitored. ALL cells that comprised the
regenerated S and PB fractions were enumerated at 5 day intervals at which time fresh
media was provided. Cultures were maintained until tumor burden compromised BMSC
or HOB monolayers.
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Western blot analysis
Specific targets of glycolytic regulation were detected by rabbit mAb Hexokinase 1 (Cell
Signaling Technologies, Danvers, MA, USA; C35C4; Cat # 2024) and rabbit mAb
Hexokinase 2 (C64G5; Cat # 2867). Following incubation with horseradish peroxidase–
conjugated secondary antibodies, signal was visualized using enhanced
chemiluminescence (Amersham, Piscataway, NJ, USA). Densitometry was quantified
by ImageJ with signal normalized to GAPDH.
Ki-67 staining
ALL subpopulations were either cytospun following G10 Sephadex purification following
co-culture or analysis was completed on ALL cells during co-culture with BMSC or HOB
grown on coverslips. Cells were fixed with 4% paraformaldehyde, washed with PBS,
permeabilized with 0.1% Triton X-100 (Sigma) in PBS, and incubated with rabbit anti-Ki67 followed by Alexa 488 anti-rabbit. Phalloidin-TRITC was used to visualize the actin
cytoskeleton. Cells were washed with PBS and mounted to glass slides (coverslip
staining) or coverslips (cytospins) with Prolong® Gold anti-fade/DAPI. Images were
acquired by confocal microscopy and a minimum of 50 cells were counted to quantitate
percent positive Ki-67 cells in triplicate.
Cell cycle analysis
G0 accumulation of ALL cells was investigated by evaluation of the DNA/RNA content
quantitated by Hoechst33342/Pyronin Y (H/PY) (Sigma) double staining as previously
described.[30] To evaluate the overall cell cycle profile of ALL cells, leukemic cells were
collected from media or the PD population of co-culture after 12 days. ALL cells were
fixed in 70% ethanol, treated with RNase (Sigma), and stained with PI for DNA analysis.
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All samples were performed in triplicate and processed on a FACSFortessia flow
cytometer, and analyzed by FCS Express 4 software.
Oxygen consumption and Extracellular Acidification analysis
Leukemic cells (800,000 cells/well) were collected from media alone or isolated from
BMSC/HOB co-culture and incubated in an XFe96 cell culture microplate coated with
Cell-Tak (BD Biosciences). The XFe 96 Analyzer with XF Assay Media containing
sodium pyruvate and glucose was used to determine Oxygen Consumption Rate [OCR]
measurements, or with XF Base Media with L-glutamine to determine Extracellular
Acidification Rate [ECAR] measurements. The XF plate was calibrated overnight with
XF Calibrant at 37ºC. On the day of the measurements, tumor cells were plated directly
in XF media, and basal measurements (OCR or ECAR) were collected at three time
points. All analysis was performed using XFe 96 Analyzer (Seahorse Bioscience, North
Billerica, MA, USA)
Laser Ablation Electrospray Ionization (LAESI) and LC-MS/MS
Leukemic cells cultured in medium alone or harvested from the PD population of BMSC
or HOB co-culture were analyzed by LAESI-MS for metabolic profiling. Quantitative
proteomic LC-MS/MS analyses were performed on the following cell treatments:
leukemic cells grown in media alone and co-culture with BMSC, BMSC/HOB, and HOB
(Protea Biosciences, Morgantown, WV, USA). Detailed methodology and statistical
analyses are included in Supplementary Materials and Methods.
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Statistical analysis
Results are expressed as mean ± SEM. An unpaired t-test was performed to analyze
results of cell viability data, H/PY, and KI67 quantitation (Graph Pad Software, La Jolla,
CA, USA). Results of basal ECAR and OCR rates were analyzed by One-way ANOVA
with Dunnett’s post hoc (Sigma Plot, San Jose, CA, USA). A p value of < 0.05 was
considered statistically significant as detailed in figure legends. Error bars throughout
figures are represent standard error (SEM).
Results
ALL cells in co-culture with BMSC or HOB form three distinct spatial
compartments.
A panel of ALL cell lines formed three spatially and phenotypically distinct populations
during co-culture with BMSC (Figure 1) or HOB (DNS). ALL cells were separated into
suspended tumor (S), which are not in physical contact with BMSC/HOB, phase bright
(PB) that are loosely adherent to BMSC/HOB and phase dim (PD) subpopulations
which bury beneath the BMSC or HOB monolayer (Figure 1). Each individual
subpopulation re-establishes the PD subpopulation when collected and placed into
subsequent co-cultures. When individual ALL subpopulations (S, PB, and PD) were
removed from BMSC or HOB co-culture, stained with distinct dyes and re-plated for 148h of interaction with BMM, no unique affinity was observed within any group of ALL
cells to repopulate the PD compartment (Figure 2).
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ALL cells located in the PD population of BMSC or HOB co-culture demonstrate
pronounced resistance to chemotherapy-induced death.
PD ALL cells in BMSC/HOB co-culture have pronounced protection from chemotherapyinduced death when compared to media alone, S, or PB tumor cells following exposure
to Ara-C, methotrexate (MTX), or vincristine (VCR) (Figure 3A-B and DNS). ALL cells
readily establish three subpopulations (S, PB and PD) when co-cultured with several
types of adherent layers established from sites other than the bone marrow, however,
the PD population is not protected from Ara-C induced cell death (Figure 3C).
Furthermore, we determined if surviving PD tumor cells from human BMSC or HOB coculture could reconstitute the culture upon conclusion of chemotherapy exposure to
simulate a purposefully simplified “in vitro relapse”. Following a quiescent period of
approximately 15 to 20 days, ALL cells from the chemotherapy resistant PD population
migrated from beneath the stromal layers and initiated proliferation to re-populate the
cultures (Figure 3D).

ALL cells influenced by BMM have altered cell cycle distribution and quiescence.
PD ALL cells have an increased G0/G1 fraction compared to media alone ALL cells
(Figure 4A). The G0/G1 combined fraction was further investigated to determine the subset of PD ALL cells that are specifically in the G0 (quiescent) phase by H/PY double
staining. Corresponding to the increase in G0/G1, PD cells have an increase in the
percentage of cells in G0 compared to ALL cells in media alone (Figure 4B). Ki-67
staining was completed for analysis of the PD ALL population (Figure 4C) with PD ALL
cells consistently having diminished Ki-67 staining when compared to media controls
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(Figure 4C-D). In addition to cell cycle analysis and Ki-67 expression alterations, global
proteomic analysis was performed. As shown in Figure 5, proteins involved in cell cycle
progression and DNA accessibility were altered in the leukemic cells influenced by the
BMM. For a select group of histone-related proteins, alterations were seen in SUP-B15
ALL cells co-cultured with BMSC versus those co-cultured with HOB.
BMSC/HOB cues alter ALL metabolic profiles.
PD ALL cells have an increased level of glycolytic activity reflected by increased
extracellular acidification rate (ECAR) when compared to ALL cells in media alone
(Figure 6A). In agreement with increased basal glycolytic activity, PD ALL cells also
have increased Hexokinase 1 and 2 protein levels (Figure 6B). While glycolytic activity
was increased in the PD population, basal levels of oxidative phosphorylation are
significantly diminished in leukemic cells in co-culture (Figure 6C). Metabolomic analysis
was completed to compare global changes between leukemic cells in the presence (PD)
or absence (media alone) of microenvironment cues with clustering of m/z according to
expression level reflecting distinct metabolic profiles (Figure 6D).

Discussion
In this study, using an extension of 2D co-culture techniques we have demonstrated
that a panel of ALL cell lines when in co-culture with BMSC or HOB form three distinct
spatial compartments: S, PB, and PD. Of these, the PD population is the most resistant
and quiescent subpopulation generated by BMM interactions in vitro, and provides a
valuable tool that can be applied for studying aggressive, resistant leukemia for targeted
intervention. To evaluate whether the three individual groups of ALL cells had specific
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affinity for the location from which they were isolated, cell tracking experiments were
completed. Leukemic cells in our model behave stochastically, and did not preferentially
reconstitute the location from which they were isolated (Figure 2). S, PB or PD derived
ALL cells readily buried under BMSC or HOB ("became PD"). This observation
suggests a very dynamic phenotype, driven by the specific cues in distinct locations,
versus a sustained phenotypic alteration or ALL cell “memory”.
Our laboratory has previously shown that in general BMSC provide chemotherapy
protection to leukemic cells via soluble factors[32,33] and adhesion interactions in
standard 2D co-cultures[15,34–36]. When the attention was directed to the PD
subpopulation, they were shown to be the most resistant to chemotherapy exposure.
Protection was specific to interactions with BMM-derived BMSC, HOB or NSG derived
BMSC (Figure 3A-C, DNS). The value of our model approach is the observation that,
with inclusion of just one niche component, either BMSC or HOB, a distinct group of
tumor cells can be isolated that have altered cell cycle profiles, metabolic signatures
and cytotoxic agent response. Future work can expand upon this model, increasing its
complexity through methodical addition of other key bone marrow microenvironment
components, such as endothelial cells[36], to better recapitulate the resistant leukemic
niche in vitro to answer specific, clinically relevant questions with emphasis on
interruption of signals that influence ALL cell quiescence, metabolic activity, and
apoptosis.
Tumor cells that are in a quiescent state have been described by other groups to be
drug resistant[37]. We observed that PD cells accumulate in the G0/G1 phase of cell
cycle with a reduction in S phase (Figure 4A). Coincident with induction of quiescence,
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PD cells had increased p27 suggesting this may be one mechanism by which the cells
are arrested in a G0 state (DNS; figure 4B). The PD population does not demonstrate
100% accumulation in G0 indicating that cell cycle interruption does not explain the
entire escape from S phase specific drug-induced apoptosis. Even within the purified
PD subpopulation multiple pathways are likely influenced by niche cells that converge
on blunting apoptosis. PD ALL cells also had a reduced proliferation index measured by
Ki-67 staining (Figure 4C-D), again consistent with the assertion that the BMM alters
ALL proliferation, which may be one contributing factor to increased chemotherapy
resistance (Figures 3-4). Future studies will be important to evaluate a broader range of
drugs in this model, including those that are not S phase specific, to expand our
understanding of the resistant subpopulation.
Diverse protein pathways were altered in leukemic cells during co-culture with BMM
cells evaluated by MS/MS analysis (Figure 5). Key pathways with significant alteration
in ALL cells were those associated with cell cycle progression and DNA accessibility.
Interestingly, differences were not only seen in ALL cells from BMM niche co-culture
compared to media alone, but also in histone related protein expression between ALL
cells influenced by BMSC compared to HOB. Although both cell types are derived from
the bone marrow, it is not surprising that they influence ALL gene expression differently
based the uniqueness of the endosteal and perivascular niches[38,39]. This reflects the
complexity of the marrow niche and compartmentalization of function that is critical for
regulated development of healthy hematopoietic cells through controlled differentiation,
proliferation, survival and eventual egress to the periphery.
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We further characterized the metabolomic profiles of the PD subpopulation compared to
tumor cells grown in media alone utilizing LAESI-MS. The metabolic signatures of
leukemic cells provided microenvironment cues were notably distinct from ALL cells
deprived of these signals (Figure 6). This global evaluation was not intended to identify
specific targets but rather to determine if overall metabolite patterns were shifted (Figure
6D). The cellular metabolism of this subpopulation of leukemic cells has been altered by
the bone marrow microenvironment interactions, resulting in quiescent cells with high
glycolytic potential (Figure 6A-B). This has been previously observed in quiescent
fibroblasts[40], and the notion that the PD cells are “primed” for proliferation when they
are released from quiescent constraints is a characteristic previously reported in
activated dormant T cells[41].
A particular concern that remains in ALL is the aggressive treatment strategies required
to treat relapse in children with the marked potential of late effects and secondary
malignancies. Against this backdrop, it is essential to expand the knowledge we obtain
in vitro for efficient translation to pre-clinical modeling, subsequent novel drug trials, and
generation of new treatment paradigms for patients. Clearly limitations are significant in
modeling a complex and dynamic disease such as ALL in vitro. The unique leukemic
co-culture model described with an emphasis on a functionally distinct, quiescent and
chemoresistant PD subpopulation provides a valuable tool for future analysis. Further
dissection of the molecular pathways regulated by the BMM and the “sanctuary” that is
created for leukemic cells to generate refractory disease still needs to be extensively
studied in order to achieve a higher percentage of disease free survival in leukemia
patients.
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Supplemental methods:
Culture conditions
Co-cultures were established by seeding leukemic cells onto 80-90% confluent BMSC
or HOB monolayers. Cultures were fed every 4 days and tumor cells collected for
inclusion in experiments with remaining leukemic cells moved to new primary BMSC or
HOB adherent layers every 12 days. Cultures were maintained in 5% O 2 to model
normal bone marrow oxygen tension, reported to range from 1-7%[1–3]. Suspended (S)
leukemic cells floating freely in the media were removed by gentle pipetting. Phase
bright (PB) tumor cells, that were loosely adherent to the top of BMSC or HOB, were
harvested by vigorous pipetting. Phase dim (PD) leukemic cells that were buried firmly
beneath adherent BMSC or HOB were recovered by trypsinization of the adherent layer
and PD tumor. The S, PB, and PD tumor populations were separated from BMSC/HOB
by size exclusion with G10 Sephadex (Sigma, St Louis, MO, USA) column
separation[4].
Microscopy
Phase contrast images were acquired using a Leica DMIL LED microscope and
processed by Leica application suite version 4.0 software (Buffalo Grove, IL, USA).
Confocal images were acquired using an upright LSM 510 Zeiss microscope and
processed using Zen2009 software (Thornwood, NY, USA). Fluorescence intensity for
image acquisition was only altered when fluorescence intensities were not compared
between samples.
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Co-culture of tumor cells with non-bone marrow derived adherent cells
ALL cells were cultured in media alone, or co-cultured with sheep choroid plexus
epithelial cells (SCP) (ATCC-CRL-1700), 3T3 mouse embryonic fibroblasts (3T3)
(ATCC-CRL-1658), mouse embryonic fibroblasts (MEF) (ATCC-CRL-2991), human
embryonic kidney cells (293T) (ATCC-CRL-3216), or HT-1080 human fibrosarcoma
derived cells (HT) (ATCC-CCL-121). Leukemic cells were cultured with adherent layers
for 4 days to establish S, PB, and PD tumor populations comparable to those
established with human BMSC/HOB. At day 4, cultures were exposed to Ara-C and
evaluated for viability by trypan blue exclusion in triplicate.
In vitro relapse model
ALL cells were grown in co-culture with BMSC or HOB for 4 days. At day 4, cultures
were provided fresh media and exposed to Ara-C for 72 hours. Following Ara-C
exposure, S and PB ALL cell subpopulations were harvested as previously described
and viability enumerated by trypan blue exclusion. Co-cultures, in which PD tumor cells
remained buried beneath adherent BMSC/HOB, were rinsed to remove residual Ara-C
and subsequently repopulation was monitored. ALL cells that comprised the
regenerated S and PB fractions were enumerated at 5 day intervals at which time fresh
media was provided. Cultures were maintained until tumor burden compromised BMSC
or HOB monolayers.
Western blot analysis
Specific targets of glycolytic regulation were detected by rabbit mAb Hexokinase 1 (Cell
Signaling Technologies, Danvers, MA, USA; C35C4; Cat # 2024) and rabbit mAb
74

Hexokinase 2 (C64G5; Cat # 2867). Following incubation with horseradish peroxidase–
conjugated secondary antibodies, signal was visualized using enhanced
chemiluminescence (Amersham, Piscataway, NJ, USA). Densitometry was quantified
by ImageJ with signal normalized to GAPDH.
Ki-67 staining
ALL subpopulations were either cytospun following G10 Sephadex purification following
co-culture or analysis was completed on ALL cells during co-culture with BMSC or HOB
grown on coverslips. Cells were fixed with 4% paraformaldehyde, washed with PBS,
permeabilized with 0.1% Triton X-100 (Sigma) in PBS, and incubated with rabbit anti-Ki67 followed by Alexa 488 anti-rabbit. Phalloidin-TRITC was used to visualize the actin
cytoskeleton. Cells were washed with PBS and mounted to glass slides (coverslip
staining) or coverslips (cytospins) with Prolong® Gold anti-fade/DAPI. Images were
acquired by confocal microscopy and a minimum of 50 cells were counted to quantitate
percent positive Ki-67 cells in triplicate.
Seahorse analysis
Leukemic cells (800,000 cells/well) were collected from media alone or isolated from
BMSC/HOB co-culture and incubated in an XFe96 cell culture microplate coated with
Cell-Tak (BD Biosciences). The XFe 96 Analyzer with XF Assay Media containing
sodium pyruvate and glucose was used to determine Oxygen Consumption Rate [OCR]
measurements, or with XF Base Media with L-glutamine to determine Extracellular
Acidification Rate [ECAR] measurements. The XF plate was calibrated overnight with
XF Calibrant at 37ºC. On the day of the measurements, tumor cells were plated directly
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in XF media, and basal measurements (OCR or ECAR) were collected at three time
points.
Laser Ablation Electrospray Ionization (LAESI)
Prior to direct analysis by laser ablation electrospray ionization (LAESI-MS) each cell
pellet (5x106 cells) was centrifuged at 1,000 x g for 2 minutes at 4°C. The entire pellet
(~3 µL) was dispensed onto a glass microscope slide for LAESI-MS analyses. In vivo
molecular profiling was performed on the cells with a LAESI DP-1000 Direct Ionization
source interfaced with a Thermo QExactive mass spectrometer (Thermo Scientific).
Electrospray solution (50% methanol/0.1% acetic acid) flowed at 1 µL/min through a
stainless steel emitter tip (320 µm OD and 100 µm ID; New Objective, Woburn, MA) at
an electrospray voltage 4 kV. Three technical replicates (250 laser pulses at 10 Hz with
a laser energy 600 µJ) were performed per three biological replicates. The LAESI peltier
stage was cooled to 4°C. Full scan mass spectrometer profiles were collected over a
mass range of m/z 50 to 750 at 35,000 mass resolution with m/z 37[5]. 1012 selected
for real-time mass accuracy lockmass correction.
Post-analysis Processing and Multivariate Statistics
Post LAESI-MS acquisition, the spectra were averaged across each technical replicate
per biological replicate (approximately 175 scans). Multivariate statistics were applied
in order to compare media treatment to BMSC and HOB, respectively. Mass Profiler
Professional (Agilent, version 13 build 211261) was used to determine significantly
altered m/z using a Benjamini Hochberg false discovery rate corrected p-value <0.01
from ANOVA testing1. Putatively altered m/z visualized using the heatmap function.
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Proteomics
iTRAQ Sample Preparation
Cell pellets were lysed 150µL of 0.1 M TEAB with 2% SDS, vortexed and sonicated for
20 minutes in an ice bath, followed by centrifugation at 12,000 g for 10 minutes.
Supernatant was quantified by BCA, and 200 µg of protein from each cell type was
precipitated using cold acetone in a 6:1 acetone to sample ratio, chilling at -20°C
overnight. Proteins were reduced and alkylated, and trypsin digested overnight. The
iTRAQ labeling (Applied Biosciences) was performed according to manufacturer’s
instructions, labeling for two hours, followed by adding an excess 350 µL of water and
incubating for 30 minutes to stop the labeling reaction. Samples Media, BMSC,
BMSC/HOB, and HOB samples were labeled with tagged with the 115, 1116, 117, 118
reagents, respectively. Samples were frozen to -80°C followed by overnight
lyophilization, and cleaned up using strong cation exchange (SCX) SpinTips (Protea
Biosciences). Samples were lyophilized after cleanup, and reconstituted in 40 µL of
0.1% formic acid/5% acetonitrile.
LC-MS/MS
Samples were separated by reverse phase chromatography using a Shimadzue LC20AD HPLC system eluting over 90 minutes using a C18 column (Kinetex 100 x 2.1 mm
C18, Phenomenex). Gradient was 0-3 minutes 2% B, 3-70 minutes 2-40%B, 70-80
minutes 90% B followed by a column wash 80-85 minutes 90% B using a flow rate of
200 µL/minute. Mobile phase A was 0.1% formic acid in water, mobile phase B was
0.1% formic acid in acetonitrile. Peptides were eluted with a positive ion mode applied
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voltage of 3.5 kV into a QTrap 5500 (AB Sciex). Using data independent acquisition, the
3 most intense multiply charged ions with ion intensities above a threshold of 50000 in
each regular MS scan were subjected to MS/MS analyses.
Data Analysis
MS/MS data were searched against the Swissprot human database downloaded
January 7, 2015. Data were searched with the Paragon search algorithm (Applied
Biosciences) through the ProteinPilot software using trypsin as the enzyme, statics
modifications of Cysteine and MMTS (Methylthio, the labeling reagent), dynamic
modifications of deamidation (N,Q) and oxidation (M). Autobias was applied for
quantification using GAPDH as a control to evaluate quantification. Altered proteins
were designated as those with p-value <0.05 relative to Media. The web applications
ToppCluster and WebGestalt were used for enrichment analysis and graphical
representation of biological processes and pathways[6,7].
Statistical analysis
Results are expressed as triplicate mean ± SEM. An unpaired t-test were performed for
viability, H/PY, and KI67 quantitation (Graph Pad Software, La Jolla, CA, USA).
Seahorse results were analyzed by One-way ANOVA with Dunnett’s post hoc (Sigma
Plot, San Jose, CA, USA). p value of < 0.05 was considered statistically significant.
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Figure legends
Figure 1. Human acute lymphoblastic leukemia cells (ALL) occupy three functionally
distinct spatial compartments during co-culture with BMSC. The left panels show
suspended ALL tumor cells from representative cell lines (REH, Nalm-27 or Tom-1)
grown in media alone. Right panels demonstrate co-culture dynamics with leukemic
cells forming three functionally distinct populations in relation to the BMSC monolayer.
Cells were co-cultured for 48 to 72h prior to acquiring images. The three ALL
populations include suspended (S) cells which refract light, appear bright and are freely
floating in culture media; phase bright (PB) tumor cells that are loosely attached to the
surface of the adherent BMSC monolayer; and phase dim (PD) tumor cells which are
beneath the BMSC monolayer and appear as phase dim cells upon light microscopy.
Arrows highlight the PD subpopulation of ALL cells in co-culture with BMSC, which are
enlarged in the inset for more detailed visualization. Scale bar= 10 µm.

Figure 2. Each subpopulation of Nalm-27 ALL cells re-established the PD fraction when
provided BMM niche cells. The S, PB and PD ALL subpopulations were collected from
co-culture and individually stained with blue, far red and green fluorophores for
visualization, respectively. Each subpopulation associated with BMSC (top panel) and
HOB (bottom panel) observed after 48h. Co-cultures were vigorously rinsed to remove
S and PB tumor cells to visualize only PD tumor cells shown in the representative
images. Actin was visualized by Phalloidin-TRITC staining. Levels including gamma
were adjusted and a median filter was applied for image clarity with no comparison of
intensity. Scale bar= 10 µm.
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Figure 3. PD leukemic cells have pronounced resistance to chemotherapy induced
death. (A) Leukemic cells recovered from the PD population of an HOB co-culture have
significantly increased viability following exposure to Ara-C [1 µM], MTX [50 µM], or
VCR [25 µM] determined by trypan blue exclusion or (B) Annexin V-FITC/PI staining
when compared to matched controls that are exposed to cytotoxic agents in media
alone. (C In contrast to human BMSC or HOB co-culture, leukemic cells recovered from
the PD population of non-bone marrow derived adherent layers do not have increased
viability compared to untreated controls during exposure to Ara-C. (D) PD leukemic cells
undergo a quiescent recovery period following Ara-C exposure, followed by an
aggressive period of proliferation to repopulate the S and PB populations. (*) denotes p
< 0.05, unpaired t-test when compared to media alone or untreated controls.

Figure 4. BMM cells influence the PD subpopulation cell cycle profile and increase
quiescence. (A) PD cells have a higher percentage of cells in the G0/G1 phase and a
reduction in S phase compared to media alone leukemic cells as measured by PI
staining. (B) H/PY staining revealed the PD cells have a higher percentage of cells in G 0
when compared to tumor cells cultured in media alone. (C) Assessing Ki-67 (green)
expression by confocal microscopy, the PD cells had a reduction in Ki-67 positive cells.
TRITC staining: red, DNA staining: blue, Ki-67: green. Scale bar equal= 10 µm. (*)
denotes p < 0.05, unpaired t-test when compared to media alone.
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Figure 5. BMM alters global protein expression in ALL cells. The heat map shown
represents differentially regulated proteins comparing Sup-B15 ALL cells co-cultured
with BMSC or HOB to those grown in media alone. GAPDH was used as a control to
normalize expression in all groups. A p-value <0.05 for comparisons of co-culture
relative to media alone was required for designation of a difference in protein
abundance.

Figure 6. PD cells isolated from bone marrow niche co-culture have a distinct metabolic
phenotype when compared to ALL cells in the absence of microenvironment signals. (A)
REH cells recovered from the PD population have increased basal glycolytic rates
compared to tumor in media alone or their S and PB counterparts from the same BMSC
or HOB co-culture as indicated by the increase in extracellular acidification rate (ECAR).
(B) Western blot analyses indicated increased Hexokinase 1 and Hexokinase 2 protein
expression in PD ALL cells compared to tumor cells maintained in media alone. (C)
REH cells in co-culture with BMSC or HOB have decreased basal oxygen consumption
compared to media alone controls as reflected by diminished oxygen consumption rate
(OCR). (D) Laser ablation electrospray ionization mass spectrometry (LAESI-MS)
metabolomic analysis of Nalm-27 cells cultured in media alone or recovered from the
PD population of BMSC or HOB co-culture showed global changes of metabolites
between ALL cells populations. Heat map represents differentially expressed metabolite
ions (m/z values), p-value < 0.01. (*) denotes p < 0.05 by One-way ANOVA with
Dunnett’s post hoc when compared to media alone.
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Figures

Figure 1. Human acute lymphoblastic leukemia cells (ALL) occupy three functionally
distinct spatial compartments during co-culture with BMSC.
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Figure 2. Each subpopulation of Nalm-27 ALL cells re-established the PD fraction when
provided BMM niche cells.
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Figure 3. PD leukemic cells have pronounced resistance to chemotherapy induced
death.
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Figure 4. BMM cells influence the PD subpopulation cell cycle profile and increase
quiescence.
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Figure 5. BMM alters global protein expression in ALL cells.
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Figure 6. PD cells isolated from bone marrow niche co-culture have a distinct metabolic
phenotype when compared to ALL cells in the absence of microenvironment signals.
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Abstract

The bone marrow niche has a significant impact on acute lymphoblastic leukemia (ALL)
cell phenotype. Of clinical relevance is the frequency with which quiescent leukemic
cells, in this niche, survive treatment and contribute to relapse. This study suggests that
marrow microenvironment regulation of BCL6 in ALL is one factor that may be involved
in the transition between proliferative and quiescent states of ALL cells. Utilizing ALL
cell lines, and primary patient tumor cells we observed that tumor cell BCL6 protein
abundance is decreased in the presence of primary human bone marrow stromal cells
(BMSC) and osteoblasts (HOB). Chemical inhibition, or shRNA knockdown, of BCL6 in
ALL cells resulted in diminished ALL proliferation. As many chemotherapy regimens
require tumor cell proliferation for optimal efficacy, we investigated the consequences of
constitutive BCL6 expression in leukemic cells during co-culture with BMSC or HOB.
Forced chronic expression of BCL6 during co-culture with BMSC or HOB sensitized the
tumor to chemotherapy induced cell death. Combination treatment of caffeine, which
increases BCL6 expression in ALL cells, with chemotherapy extended the event free
survival of mice. These data suggest that BCL6 is one factor, modulated by
microenvironment derived cues that may contribute to regulation of ALL therapeutic
response.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. While
two-thirds of cases present in children, the risk of ALL also increases with age in the
adult population [1]. In both populations, relapse of disease is associated with poor
prognosis, with relapsed disease often being more aggressive and refractory to
treatment [2, 3]. Risk of relapse has been shown to be linked to the presence of
refractory minimal residual disease (MRD) [4– 6]. The bone marrow is the most
common site of ALL MRD, and consequently, the most common site of relapse [7].
Consistent with relapse in the bone marrow microenvironment (BMM), we and others
have shown that bone marrow stromal cells (BMSC) and osteoblasts (HOB) provide
protection to leukemic cells during chemotherapy treatment [8– 16]. However, the cell
signaling pathways by which the BMM influences tumor cells to provide this protection
remains incompletely understood.
While there are many diverse signaling pathways that converge on the
phenotype of any tumor in response to microenvironment derived cues, the focus of the
current investigation is on the modulation of ALL cell BCL6. BCL6 is a proto-oncogene
that has been classically described in the setting of its influence on germinal center Bcells, as well as its role in the progression of diffuse large B-cell lymphoma [17– 28]. In
these contexts, BCL6 has been well characterized as a regulator of B-cell proliferation,
maturation, and resistance to DNA damage [29]. More recent work has highlighted the
impact of BCL6 on immature and malignant hematopoietic cells. Increased expression
of BCL6 in chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia
(ALL) has been shown to protect leukemic cells from chemotherapy induced DNA
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damage through the repression of p53 induced apoptosis [30, 31]. These studies, in
addition to earlier work in germinal center biology, reflect the ability of BCL6 to influence
leukemic cell phenotype through regulation of survival, differentiation, and cell cycle
progression.
To address a fundamental gap that exists in understanding how the BMM
impacts leukemic BCL6 we utilized the previously described in vitro model in which
phase dim (PD) ALL cells migrate beneath BMSC or HOB and exhibit a chemotherapyresistant phenotype. Our laboratory has previously characterized this dynamic in vitro
model in which ALL cells seeded onto BMSC or HOB transiently migrate beneath the
bone marrow stromal layer, generating the “phase dim” population [13, 15]. This
population of ALL cells was characterized by quiescence and chemotherapy resistance
while in this in vitro niche. However, removal from beneath the stromal layer results in a
return to chemotherapy sensitivity [13]. Furthermore, this PD characteristic was specific
to ALL cells co-cultured with BMSCs or HOBs, as PD populations, which readily
migrated beneath co-cultures comprised of non-bone marrow derived adherent layers,
were not protected from chemotherapy-induced death [13] suggesting the observed
effect is not simply physical protection from cytotoxic drugs. Utilizing this co-culture
model to represent BMM protected and resistant ALL cells we found that co-culture with
BMSC or HOB reduced the abundance of tumor cell BCL6, coincident with increased
survival and quiescence of a subset of tumor cells in contact with BMSC or HOB.
Furthermore, chronic forced expression of BCL6 in this quiescent tumor cell population
resulted in sensitization to chemotherapy. These observations suggest that the BMM
influenced leukemic cell BCL6 protein abundance has the potential to contribute to the
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generation of a quiescent, drug resistant population of tumor cells and that strategies
aimed at disruption of this pathway may prove to be an effective means by which to
diminish MRD and relapse of ALL.
Results
Co-culture with BMSC or HOB reduces BCL6 in ALL cells.
Both the BMM in general, and BCL6 specifically, have independently been shown to
regulate ALL survival [11– 14, 30, 31]. However, it has not been determined whether
there is a functional link between bone marrow niche derived signals and ALL cell
abundance of BCL6. To determine whether BMM cells regulate BCL6 protein levels in
leukemic cells, ALL cell lines were grown in co-culture with either BMSC or HOB and
compared to tumor cultured in media alone. Co-culture derived tumor cells were further
sub-divided into distinct populations that included suspended (S), phase bright (PB),
and phase dim (PD) leukemic cells based on their spatial location within the co-culture.
We have previously observed that in vitro location related to BMSC or HOB stromal
cells impacts ALL survival in co-culture during chemotherapy exposure, with the PD
population of leukemic cells being the most resistant to chemotherapy exposure [13, 15]
providing an opportunity to focus studies uniquely on the most resistant subpopulation
of tumor cells. In the current study, regardless of the fraction of ALL cells evaluated,
decreased BCL6 protein abundance was observed in ALL cells co-cultured with BMSC
or HOB, with the most pronounced reduction consistently observed in the PD population
(Figure 1 A-B). Of note, under normal culture conditions there is no difference in ALL
cell viability between cells cultured in media alone compared to those in the co-culture
conditions (DNS) supporting the observation that changes in BCL6 abundance are not
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due to selective pressure of the different culture conditions, but are a result of
interactions with the BMSC or HOB. Consistent with western blot observations, flow
cytometry and confocal microscopy analysis of REH and Nalm-27 cell lines showed that
leukemic cells recovered from the PD population of BMSC or HOB co-culture had
reduced BCL6 protein abundance compared to tumor cells cultured in media alone
(Figure 1B and D). Consistent with data derived from cell lines, ALL patient derived cells
co-cultured with BMSC or HOB also had decreased BCL6 protein levels compared to
cells grown in media alone (Figure C and E).
Modulation of BCL6 alters ALL cell cycle progression and proliferation rate.
Based on reports of BCL6 abundance influencing proliferation of B-cells [32– 35], we
determined the functional consequence of BCL6 downregulation on ALL cell
proliferation and cell cycle progression. Inhibition of BCL6 with the small molecule
inhibitor 79-6 resulted in a significant decrease in expansion of ALL cells in media alone
compared to DMSO solvent controls (Figure 2A) without an effect on tumor cell viability
(Figure 2B). Proliferation of ALL cells was reduced by BCL6 inhibition as reflected by a
significant reduction in the proliferation index of ALL cells exposed to 79-6 (Figure 2C).
Consistent with reduced ALL cell number and proliferation, BCL6 inhibition altered cell
cycle progression in ALL cells as shown by an increase in G0/G1 phases and reduction
in S and G2/M phases (Figure 2D). Because there is always concern regarding the
potential for non-specific effects when using small molecule inhibitors, we generated
lentiviral based shRNA knockdown of BCL6 in REH cells. This more specific targeted
approach resulted in diminished proliferation as determined by a decrease in cell
density over time relative to vector controls (Figure 2E; left panel). Conversely,
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overexpression of BCL6 in REH cells increased cell density compared to vector controls
in a time course assay (Figure 2E; right panel). Knockdown of BCL6 also significantly
increased the percentage of REH tumor cells in G0/G1 phases and reduced G2/M
phases in line with the observed reduction of cell density in the time course assay
(Figure 2F; left panel). Overexpression of BCL6 decreased the fraction of ALL cells in
G0/G1 phases and increased tumor numbers in S phase (Figure 2F; right panel),
although these changes were not statistically significant their trend is consistent with the
cell density assay.
BCL6 expression in ALL cells impacts abundance of cell cycle regulatory protein
cyclin D3.
Cyclin D3 has been shown to be an important cell cycle regulatory protein in germinal
center B-cells, which is also a site where BCL6 is actively modulated to promote
proliferation [36]. Based on these observations, we investigated whether BCL6
modulation impacts expression of cyclin D3. Consistent with BCL6 protein levels, cyclin
D3 protein abundance was decreased in PD REH and Nalm-27 ALL cells compared to
tumor cells grown in media alone (Figure 3A). Knockdown of BCL6 in ALL cells reduced
the protein abundance of cyclin D3, and BCL6 overexpression increased cyclin D3
protein levels (Figure 3B). In addition, chemical inhibition of BCL6 by 79-6 led to
diminished cyclin D3 protein abundance in ALL cells (Figure 3C).
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Chronic overexpression of BCL6 sensitizes the chemotherapy-resistant PD
population to chemotherapy.
Many ALL chemotherapy regimens rely on tumor cell proliferation as a requirement for
optimal induction of cell death. Consequently, these strategies tend to be less effective
against quiescent tumor cells [12, 37]. With the observation that reduced BCL6 in PD
ALL cells results in a quiescent phenotype, we aimed to investigate strategies that
target this chemotherapy-resistant population through modulation of BCL6. REH tumor
cells with constitutive overexpression of BCL6 in the PD population showed a significant
reduction in viability when compared to vector controls following exposure to
chemotherapy (Figure 4A). PD tumor cells were “rescued” from BCL6 overexpression
by BCL6 chemical inhibition, as demonstrated by the increase in PD REH cell viability
following 79-6 and chemotherapy exposure relative to the overexpression only cells
(Figure 4A). Based on this observation we identified chemical compounds that influence
BCL6 protein levels. MG132 and caffeine have been shown to increase BCL6 protein
abundance in cells by preventing the degradation of BCL6 [27]. While it is appreciated
that neither MG132 or caffeine are specific regulators of BCL6, and that the effects of
either could be on an upstream modulator of BCL6, our findings showed that MG132 or
caffeine exposure resulted in increased BCL6 protein in ALL cells (Figure 4B). Given
that PD cells have less BCL6 and are more resistant to chemotherapy, we investigated
whether MG132 or caffeine exposure increased BCL6 in PD ALL cells. Exposure to
either MG132 or caffeine increased BCL6 protein abundance in PD ALL cells (Figure
4C). Consistent with our previously published data [13, 15], PD ALL cells in both BMSC
and HOB are protected from chemotherapy exposure relative to their media alone
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counterparts as indicated by significantly increased viability following Ara-C exposure
(Figure 4D). However in both REH and Nalm-27 cells, pretreatment with MG132 or
caffeine 6 hours prior to Ara-C exposure sensitized the resistant PD ALL cell population
to chemotherapy-induced death as shown by a significant reduction in cell viability
compared to the group treated with Ara-C alone (Figure 4D).
Forced expression of BCL6 in ALL cells increases chemotherapeutic response.
Residual tumor cells in the bone marrow following chemotherapy treatment is a
prognostic indicator of patient outcome [4– 6]. Based this well-established indicator we
evaluated tumor burden in the bone marrow of NOD-SCID gamma (NSG) mice
following treatment with chemotherapy (Figure 5A). Although not statistically significant
mice injected with ALL cells overexpressing BCL6 had a lower median percentage
(45.6% GFP+) of human tumor cells compared to those injected with vector control cells
(54.1% GFP+) 24 hours after the conclusion of Ara-C treatment (Figure 5B). Because
MG132 and caffeine sensitized the chemotherapy-resistant PD ALL cells to
chemotherapy in vitro (Figure 4D), we investigated whether MG132 or caffeine could
increase event free survival in a NSG model of ALL disease (Figure 5C). Corresponding
to the in vitro observations, mice pretreated with caffeine 6 hours prior to Ara-C
treatment had significantly increased event free survival time compared to mice treated
with Ara-C only (Figure 5D).
Discussion
In the current study, we investigated the role that bone marrow stromal cells and
osteoblasts have on the modulation of BCL6 levels in ALL, and the influence of BCL6
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on resistance to chemotherapy. While there are numerous established BMM
interactions that regulate ALL proliferation and chemotherapy resistance, to our
knowledge this work represents the first time microenvironment regulation of ALL BCL6
abundance has been explored. Utilizing BMSC and HOB as just two representative
elements of the protective BMM niche, we observed that co-culture reduces tumor cell
BCL6 expression compared to ALL cells cultured in media alone (Figure 1) and that
removal of ALL cells from the PD “niche” buried beneath BMSC or HOB to media alone
results in increased BCL6 protein abundance (DNS). The reduction of BCL6 in ALL cells
that are in co-culture with bone marrow derived adherent stromal cells or osteoblasts is
most pronounced in the PD sub-population of ALL cells, which we have previously
reported as the most quiescent and refractory to chemotherapy [13, 15]. The quiescent
phenotype appears to be regulated, in part, through BCL6 impact on ALL cell cycle
progression. Both chemical inhibition and targeted knockdown of BCL6 in ALL cells
resulted in diminished proliferation and accumulation of cells in the G0/G1 phase of cell
cycle (Figure 2). Likewise, increased abundance of BCL6 led to sustained proliferation
and a higher percentage of cells in S phase (Figure 2) when compared to vector control
cells. The ability of BCL6 to regulate the transition of cells between quiescent and
proliferative states is reminiscent of its function in germinal center B-cells where
elevated BCL6 acts to promote high rates of proliferation [33– 35]. Consistent with the
broadly recognized complexity of the impact of BCL6 on cell fate, it has been shown
that, in contrast to our findings, BCL6 upregulation in some settings promotes a
quiescent phenotype [38– 40]. These differences are not surprising as BCL6 is known
to interact with, and regulate, a variety of cellular programs in a context dependent
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manner [reviewed 41– 43] and highlights the importance of investigating BCL6 in the
specific setting of microenvironment regulation and to interpret observations with the
appropriate model driven limitations in mind. In the current study, we show that BCL6
influences proliferation of ALL cells and that its abundance is influenced by the
interaction with elements of the BMM (Figure 1 and 2). In addition, our observations
suggest that cyclin D3 protein levels in ALL cells are, in part, regulated by BCL6. Both
chemical inhibition and more specific shRNA knockdown of BCL6 in ALL cells reduced
cyclin D3 levels with BCL6 overexpression correlated with increased cyclin D3 protein
abundance (Figure 3). This observation is significant as cyclin D3 has been reported to
be an important regulator of mature and immature B-cell cell cycle progression through
G1 phase [36, 44, 45]. While the precise mechanism by which the BMM is regulating
BCL6 abundance in ALL cells remains unknown, one possibility that warrants
consideration is that BCL6 protein being regulated via niche derived cues that impact on
phosphorylation, targeting it for proteasomal degradation. Based on previously
described pathways that regulate BCL6 [27, 46, 47] and our observations using
proteasome inhibitors (Figure 4), as well as, the lack of significant change in BCL6
mRNA levels in tumor cells co-cultured with BMSC or HOB (DNS), regulation at the
protein level is implicated. Future work which focuses investigation on this potential
mechanism will be important, however this is beyond the scope of the current study.
While additional studies will be required to focus on a greater understanding of the
interactions between the BMM and ALL cells that drive the reduction in BCL6, our
results suggest that the quiescent phenotype exhibited by ALL cells in the BMM niche is
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in part modulated through microenvironment regulation of ALL cell BCL6 protein. This in
turn appears to regulate cell cycle progression, potentially through control of cyclin D3.
In both normal and malignant B-cells, increased expression of BCL6 has been
shown to promote cell survival through inhibition of the p53 pathway, which allows for
tolerance to DNA damage within cells [20, 30, 31]. In ALL cells, increased expression of
BCL6 results in a tolerance to DNA damage and subsequently increased survival during
BCR–ABL1 kinase inhibition [30]. Conversely, our observations suggest that decreased
abundance of BCL6 subsequent to interaction of leukemic cells with BMSC or HOB can
also protect ALL cells from death through induction of a quiescent phenotype.
Furthermore, chronic overexpression of BCL6 appears to sensitize tumor cells to
chemotherapy exposure coincident with increased ALL cell proliferation and blunted
tumor cell quiescence (Figure 2 and 4). We speculate based on the work of others, as
well as these observations that dynamic regulation of BCL6 in ALL regulates survival
when challenged by stress such as chemotherapy. These observations suggest that
increased BCL6 protein levels during chemotherapy may allow tolerance of DNA
damage, with subsequent downregulation of BCL6 required for cells to enter a
quiescent state during which DNA can be repaired. Interference of this dynamic
balance, such as that imposed by chronic sustained expression of BCL6, appears one
way in which to sensitize BMM protected ALL cells to chemotherapy treatment (Figure
4-5). Due to the complexities of both BMM signaling and BCL6 regulation, additional
studies will be needed to determine how these dynamic regulatory pathways affect
survival pathways including p53, ATM/ATR, and BCL family proteins within ALL cells
and how this may promote resistant disease in the marrow niche.
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Consistent with the in vitro findings, in vivo chronic overexpression of BCL6
during Ara-C treatment resulted in a modest reduction in the tumor burden in femurs of
mice when collected 24 hours following the conclusion of Ara-C treatment (Figure 5B).
In addition, using a model based on that which was previously described with the
readout of event free survival [48– 50], we observed that caffeine pre-treatment,
shown to increase BCL6 [27], significantly extended event free survival in a NSG mouse
model of ALL (Figure 5D). While recognizing that caffeine does not specifically target
BCL6 exclusively, it may serve as a safe tool to, at least in part, modulate BCL6
expression. Diminished tumor burden in the bone marrow and event free survival have
both been shown to be significant prognostic indicators of patient outcome in response
to chemotherapy [5, 7, 51] and these findings illustrate the significance of the observed
increase in event free survival time of mice following combination treatment with
caffeine and Ara-C. We also hypothesize that this type of combination treatment
strategy might be advantageous during consolidation therapy as a means to “activate”
residual quiescent ALL cells to be better targeted by cytotoxic regimens. In this context,
caffeine is an attractive treatment strategy due to its long history of safe use in humans
[52] and our results which show it can sensitize microenvironment protected ALL cells to
chemotherapy treatment (Figure 4-5). As with all models in immunocompromised mice
there are limitations to interpretation, however, they serve as an important setting in
which to test general concepts and to identify potentially important pathways around
which to focus novel intervention strategies.
In summary, the goal of this study was to investigate how BMSC and HOB,
components of the protective bone marrow niche, would influence the levels of BCL6 in
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ALL cells. We report that ALL cell lines, as well as primary patient samples, co-cultured
with BMSC or HOB, have reduced BCL6 protein. This reduction in BCL6 abundance
was most pronounced and consistently observed in leukemic cells recovered from the
PD population, which we have previously characterized as a chemotherapy-resistant
population representative of resistant tumor populations [13, 15]. Decreased BCL6 in
ALL cells affects the cell cycle profile and promotes a quiescent phenotype. This
phenotype appears to be coincident with BCL6 reduction and decreased cyclin D3; a
consequence that has been reported to regulate progression through the G1 phase of
cell cycle [36, 44, 45]. Chronic overexpression of BCL6, achieved either through
overexpression vectors or chemical intervention by MG132 or caffeine, sensitized ALL
cells that are generally protected by BMSC or HOB from chemotherapy induced death.
Furthermore, combination treatments using caffeine to stabilize BCL6 levels followed by
Ara-C exposure significantly increased the event free survival of mice in which ALL had
been established. Collectively, these results suggest that strategies which disrupt
microenvironmental regulation of BCL6 in ALL cells may be an effective strategy to
sensitize quiescent, chemotherapy-resistant leukemic cells to treatment, eliminating
MRD in the protective bone marrow niches and reducing the incidence of relapse.
Methods
Cell lines and culture conditions
Philadelphia chromosome positive (Ph+) lymphoblastic cell lines Nalm-27 (Fujisaki
Cancer Center) and Sup-B15 (ATCC-CRL-1929), and Ph- REH (ATCC#CRL-8286)
were utilized. De-identified primary human leukemic cells were acquired from the West
Virginia University Health Sciences Center and West Virginia University Cancer Institute
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tissue bank. Primary patient sample 1 (P1) is a MLL rearranged (11q23) B-lineage ALL
isolated from a 43 year old female at diagnosis. Primary patient sample 2 (P2) is a (Ph -)
B-cell ALL/LBL isolated from a 65 year old male at diagnosis (45-46, XY, t(411)(q21;q23), add (6)(p25), -21, +1-2mar[12]/46, XY[8]). De-identified primary bone
marrow stromal cells (BMSC) were provided by the West Virginia University Cancer
Institute Biospecimen Processing Core and the West Virginia University Department of
Pathology Tissue Bank. BMSC cultures were established as previously described [53].
Human osteoblasts (HOB; PromoCell) were cultured according to the supplier’s
recommendations. Co-cultures of adherent bone marrow derived supportive cells and
ALL cells were established by seeding leukemic cells onto 80-90% confluent BMSC or
HOB monolayers. Cultures were fed every 4 days and tumor cells collected for inclusion
in experiments. Remaining leukemic cells were moved to new primary BMSC or HOB
adherent layers every 12 days. Cultures were maintained in 5% O 2 to model normal
bone marrow oxygen tension, reported to range from 1-7% [54, 55]. Suspended (S)
leukemic cells floating freely in the media; phase bright (PB) tumor cells, that were
loosely adherent to the top of BMSC or HOB; and phase dim (PD) leukemic cells that
were buried firmly beneath adherent BMSC or HOB were collected as distinct
populations as previously described [13, 15]. The S, PB, and PD tumor populations
were separated from BMSC or HOB by size exclusion with G10 Sephadex (Sigma)
column separation as previously described [13, 15, 56].
Flow Cytometric quantification of BCL6 expression
REH and Nalm-27 tumor cells were cultured and PD ALL cells were harvested as
described above. P1 and P2 were cultured in media alone or co-cultured with BMSC or
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HOB for 2 days prior to analysis to utilize them prior to significant loss in viability.
Experiments that included primary tumor cells required collection of all tumor that was in
physical contact with the BMSC or HOB (PB + PD) to provide sufficient numbers for
analysis. ALL cells were stained using Cell Signaling Technology’s recommended
protocol for intracellular BCL6 staining using primary antibodies rabbit anti-BCL6 (Cat #
14895) (1:300) or Rabbit (DA1E) mAb IgG XP isotype control (Cat # 3900). Cells were
washed with 1x PBS and incubated with secondary antibody goat anti-rabbit Alexa Flour
647 (Invitrogen; Cat # A21244) [1 µg/mL]. Collection and analysis were performed using
the LSRFortessa (Becton Dickenson, San Jose, CA, USA).
Immunofluorescence imaging
Confocal images were acquired using an upright LSM 510 Zeiss microscope and
processed using Zen2009 software and Adobe Photoshop with fluorescence intensity
held constant for any experiment in which image acquisition was compared across
samples. ALL cells were cytospun on glass slides following G10 Sephadex purification.
Cells were fixed with 4% PFA, blocked in 1x PBS/ 5%FBS/ 0.3% Triton X-100, washed
with 1x PBS, and incubated with rabbit anti-BCL6 (Cell Signaling Technology, Cat #
14895) (1:100) followed by anti-rabbit Alexa 647 (Invitrogen; Cat # A21244) (1:200).
Slides were washed with PBS and mounted to coverslips using Prolong® Gold antifade/DAPI overnight (Life Technologies).
Cell proliferation assay
ALL cells were labeled using the cell retention dye CellTrace-CFSE Cell Proliferation Kit
(Life Technologies, Cat # C34554) as described by the manufacturer. Cells were then
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cultured under normal growth conditions for 2 days in either media DMSO control or
media with 79-6. CellTrace fluorescence intensity was measured by flow cytometry
using FACSFortessia. Proliferation indices were calculated using FCS Express4.
Cell cycle analysis
ALL cells were fixed in 70% ethanol, treated with RNase (Sigma), and stained with
propidium iodide (PI) for DNA analysis. All samples were performed in triplicate,
processed on a FACSFortessia flow cytometer and analyzed using FCS Express4
software.
Western blot analysis
Rabbit polyclonal BCL6 (Cat # 5650) and Cyclin D3 (Cat # 2936) were purchased from
Cell Signaling Technology and used at 1:1000 dilution. Mouse polyclonal anti-GAPDH
was purchased from Fitzgerald Inc. (Cat # 10R-G109a). Proteins were resolved on
SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were
blocked in TBS 5%/nonfat dry milk 0.05% Tween-20 and probed with the indicated
primary antibodies. After incubation with horseradish peroxidase–conjugated secondary
antibodies, signal was visualized using enhanced chemiluminescence reagents
(Amersham). Western blots are representative of at least 3 independent experiments.
Densitometry quantification is indicated and was completed using ImageJ software.
Drugs and chemotherapeutic reagents
Cytarabine (Ara-C) (Selleckchem, Cat # S1648), Methotrexate (MTX) (Selleckchem, Cat
# S1210), Vincristine (VCR) (Selleckchem, Cat # S1241), MG132 (Selleckchem, cat #
S2619), Caffeine (Sigma-Aldrich, Cat # C0750), and 79-6 (Calbiochem, Cat # 197345)
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were diluted and stored per manufacturer recommendations. For in vitro experiments
drug stocks were diluted in base media and for in vivo experiments stocks were diluted
in saline immediately prior to use. In vitro concentrations of Ara-C [1 µM], MTX [50 µM],
VCR [25 µM], MG-132 [1-5 µM], caffeine [2.5-10 mM], and 79-6 [125 µM] were used to
approximate clinically relevant doses in ALL or published in vitro concentrations [27,
57– 63].
Evaluation of leukemic cell concentration and viability
ALL cells were cultured in media alone or co-cultured with BMSC or HOB for 4 days to
establish the PD tumor population. On day 4 cultures were provided fresh media and
exposed to Ara-C, MTX, or VCR for 4 additional days. Cells treated with Ara-C were retreated at 48 hours. 79-6, MG132, or caffeine were added 6 hours prior to
chemotherapy in combination experiments. Viability and cell number were evaluated by
trypan blue exclusion in triplicate.
BCL6 knockdown and overexpression
Human TRIPZ lentiviral inducible shRNAmir constructs to BCL6 clone ID numbers
V3THs_404721 (KD1) and V2THS_132926 (KD3) were purchased from Thermo
Scientific. Viral particles were produced and administered to REH ALL cells according to
manufactures protocol. shRNA expression was induced using doxycycline [1ug/mL] and
RFP positive cells were sorted by flow cytometry.
BCL6 overexpression vector was generated by removing the BCL6 gene sequence from
the MSCV-BCL6-IRES-GFP [40] which was purchased from Addgene (Plasmid 31391).
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BCL6 fragment was then ligated into pLVX-EF1α-IRES-ZsGreen1 plasmid (Clontech
Laboratories, Inc. Cat# 631982).
Mice
All experimental procedures involving NOD/SCID Gamma (NSG) mice were approved
by the West Virginia University Institutional Animal Care and Use Committee. Male
NOD/SCID Gamma (NSG) mice age 5-6 weeks were acquired from the West Virginia
University NSG colony or purchased from the Jackson Laboratory. To determine
whether chronic BCL6 overexpression would sensitize ALL cells to chemotherapy
treatment, resulting in reduced tumor burden in the bone marrow, NSG mice were
divided into two groups and tail vein injected with 2 x106 REH cells expressing
BCL6/GFP or vector/GFP control. Peripheral tumor burden was monitored via tail vein
draws to collect approximately 30µL of blood. Red blood cells were lysed (150 mM
NH4Cl, 10 mM NaHCO3 and 0.1 mM EDTA in distilled water) and ALL cell frequency
was evaluated by flow cytometry analysis of GFP positive human cells relative to total
mononuclear cells. Chemotherapy treatment began when the peripheral blood burden
of the group reached 1-5% GFP positive cells which has been previously reported to
indicate established leukemic disease [48]. Ara-C treatment was administered by
intraperitoneal (IP) injection at a concentration of 100 mg/kg daily for 3 consecutive
days. Mice were euthanized 24 hours after the final Ara-C treatment and bone marrow
was collected from femurs to quantify percentage of GFP positive tumor cells in the
bone marrow by flow cytometry.
To determine whether combination treatment of mice with the BCL6 modulating
agents MG132 or caffeine would sensitize ALL cells to chemotherapy, 2x106 REH cells
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expressing the vector/GFP construct were injected via tail vein to establish leukemic
disease. Tumor burden was monitored as previously described. When peripheral blood
burden of the group reached an average of 1-5% GFP positive cells relative to total
mononuclear cells, mice were randomly assigned to treatment groups. Treatments
included saline control, MG132 [1 mg/kg], Caffeine [50 mg/kg], Ara-C [100 mg/kg],
MG132 [1mg/kg] + Ara-C [100 mg/kg], or Caffeine [50 mg/kg] + Ara-C [100 mg/kg]. All
drugs were diluted in saline prior to injection and were administered by IP injection.
MG132 and caffeine were given 6 hours before treatment with Ara-C with mice treated
for 3 consecutive days. Event free survival (EFS) was calculated from the start of
treatment as previously described [48] with an event defined as 25% GFP positive cells
in the peripheral blood by flow cytometric analysis or when mice showed clinical signs of
disease (lethargy, weight loss, ruffled fur).
Statistical analysis
All data are presented as mean ± standard error and the statistical significances
between conditions was determined by the student’s t test or 2-way ANOVA with HolmSidak post-hoc test using GraphPad or SigmaPlot software. All in vitro results generated
from cell line derived data are representative of at least 3 independent experiments.
Experiments with primary patient samples are representative of at least 2 independent
experiments. Kaplan-Meier survival curves were generated for event free survival and a
fitted Cox model was used to determine p-values.
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Figure legends
Figure 1. Co-culture with BMSC or HOB reduces BCL6 in ALL cells. A. BCL6
protein in REH and Nalm-27 ALL cells when co-cultured with BMSC or HOB cells
relative to media (M) controls as shown by western blot analysis. B. Flow cytometry
analysis of REH and Nalm-27 ALL cell BCL6 protein levels when removed from the PD
population compared to cells in media alone as shown by median florescence intensity
(MFI). C. MFI of Patient 1 (P1) and Patient 2 (P2) when in physical contact with BMSC
or HOB compared to those in media alone (ND= not detected). D. Confocal microscopy
images of REH and Nalm-27 for BCL6 (yellow) and DAPI (Blue) in cells cultured in
media alone compare to those recovered from the PD population of BMSC or HOB coculture. E. P1 and P2 BCL6 confocal staining of media alone cells relative to those in
contact with BMSC or HOB. Scale bar = 10µm.
Figure 2. Modulation of BCL6 alters cell cycle progression and proliferation of
ALL cells. A.- B. Cell density and viability of REH, Sup-B15, and Nalm-27 following
exposure to the small molecule BCL6 inhibitor 79-6 (125µM) relative to DMSO controls
as shown by trypan blue exclusion cell counts. C. Proliferation index of 79-6 treatment
of REH, Sup-B15 and Nalm-27 ALL cells compared to DMSO controls using a CSFE
cell retention dye flow cytometry analysis. D. Propidium iodide (PI) DNA staining for cell
cycle assessment of REH, Sup-B15 and Nalm-27 treated with 79-6 compared to DMSO
controls. E. Cell density of shRNA knockdown of BCL6 (KD1 and KD3) (left panel) and
BCL6 overexpression (BCL6 OX) (right panel) of REH cells over time compared to
vector controls as evaluated by trypan blue exclusion counts. F. Cell cycle analysis of
BCL6 knockdown (left panel) and BCL6 overexpression (right panel) in REH cells using
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PI staining. (* = p<0.05 for 79-6 treated cells or knockdown/overexpression cells
compared to DMSO or vector controls, respectively).
Figure 3. BCL6 modulates the cell cycle regulating protein cyclin D3. A. Western
blot analysis of protein abundance of BCL6 and cyclin D3 in REH and Nalm-27 cells in
media alone compared to PD cells recovered from BMSC or HOB co-culture. B.
Comparison of REH BCL6 knockdown and overexpression to vector controls for BCL6
and cyclin D3 protein levels by western blot. C. Protein analysis by western blot of cyclin
D3 in REH and Nalm-27 cells when exposed to 79-6.
Figure 4. Forced expression of BCL6 sensitizes PD ALL cells to chemotherapy
exposure. A. Viability comparison of REH vector control, BCL6 overexpression, or
BCL6 overexpression cells pre-treated with 79-6 (125µM) following exposure to three
chemotherapy drugs (Ara-C [1 µM], MTX [50 µM], VCR [25 µM]). (* = p<0.05 BCL6 OX
to vector control and # = p<0.05 BCL6 OX to BCL6 + 79-6). B. REH and Nalm-27 BCL6
protein dose response to MG132 and caffeine as shown by western blot. C. Western
blot analysis to determine BCL6 protein abundance of REH and Nalm-27 cells when
exposed to MG132 or caffeine when recovered from media alone, and the PD
population of BMSC or HOB co-culture. D. REH and Nalm-27 cell viability following
exposure to Ara-C alone or when pre-treated with MG132 or caffeine 6 hours prior to
Ara-C exposure to compare cells in media alone to those recovered from the PD
population of BMSC or HOB co-culture. (# = p<0.05 PD ALL cells from BMSC/HOB
relative to media and *= p<0.05 Ara-C + MG132/ Ara-C + caffeine relative to Ara-C only
treatment).
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Figure 5. In vivo sensitivity to Ara-C is increased by BCL6 overexpression or pretreatment with caffeine. A. Schematic of NSG mouse experiment to determine GFP+
ALL burden in the femurs of NSG mice. B. Box plot representation of median
percentage of GFP+ REH ALL cells relative to total mononuclear cells recovered from
femurs of NOD-SCID Gamma (NSG) mice infected with REH vector control (n=5) or
REH BCL6 overexpression (n=4) ALL cells following three consecutive days of Ara-C
treatment. C. Schematic of NSG mouse experiment to determine event free survival of
mice pre-treated with BCL6 modulating drugs MG-132 or caffeine. D. Event free survival
of NSG mice following treatment with Ara-C (n=5), MG-132 + Ara-C (n=6), or caffeine +
Ara-C (n=6) (* =p<0.05 Ara-C relative to caffeine+ Ara-C).
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Figures

Figure 1. Co-culture with BMSC or HOB reduces BCL6 in ALL cells.
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Figure 2. Modulation of BCL6 alters cell cycle progression and proliferation of ALL cells.
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Figure 3. BCL6 modulates the cell cycle regulating protein cyclin D3.
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Figure 4. Forced expression of BCL6 sensitizes PD ALL cells to chemotherapy exposure.
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Figure 5. In vivo sensitivity to Ara-C is increased by BCL6 overexpression or pretreatment with caffeine.
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Chapter 5

General Discussion
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Modern chemotherapy regimens have transformed the once 100% fatal disease
of acute lymphoblastic leukemia into a malignancy that has one of the best prognoses
among all cancers. While diverse age groups are diagnosed with ALL, it is most
common in children between the ages 2-5 years old1,2. The predominance of this
disease in the pediatric population highlights concerns about the necessity of dose
escalated chemotherapy and repeated exposure to cytotoxic drugs as noted in Chapter
1. The positive aspect of ALL treatment is that the 5-year relative survival for all ALL
patients has risen from 31% in 1975 to 67.5% based on data collected from 200520112. In addition to increased 5-year survival rates, complete remission rates for both
children and adults has steadily improved with complete remission achieved in greater
than 90% of childhood cases and more than 80% of adult cases1–3. These results
indicate the great strides that have been achieved in the treatment of this disease. Yet,
the overall 5-year survival rate of 67.5% indicates that a number of patients who
achieve initial remission will subsequently relapse. Relapse of ALL occurs at a rate of
20-25% in children and greater than 50% of adult cases4–8. Relapse of ALL is often
coincident with aggressive disease and poor prognosis and highlighted in Chapter 1. Of
clinical significance is the frequency with which ALL relapse arises from the bone
marrow. Relapse from this anatomical site, as well as the length of the initial remission,
is associated with a poor prognosis relative to events arising later and from other
sites9,10. Based on this observation, research focused on the interactions between the
BMM and ALL that promote chemotherapy resistance disease is of significant
importance in the continued progression toward eradication of ALL.
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To address questions centered on crosstalk between the BMM and ALL that
result in refractory disease, we aimed to improve current in vitro co-culture models to
better model the most chemotherapy resistant ALL cells supported by the bone marrow
niche. Work using normal CD34+ hematopoietic cells in co-culture with MSCs revealed
that hematopoietic cells will interact with an adherent monolayer of MSCs to form three
distinct spatial populations of hematopoietic cells11. This group termed the
subpopulations that form as suspended (S), which are cells freely floated in the media;
phase bright (PB) that adhered to the surface of the MSCs; and the phase dim (PD)
which buried beneath the MSC monolayer11. In these distinct subpopulations, it was
noted that proliferation and differentiation of the CD34+ cells was influenced by their
location within the co-culture11. As highlighted in Chapters 2 and 3, we built upon these
findings to determine whether ALL cells in co-culture with BMSC or HOB would form
three spatial populations in relation to the adherent monolayers. We found that ALL
cells, similar to their normal hematopoietic counterparts, readily established three
populations within the co-culture system12,13. To accurately, efficiently, and reproducibly
generate this ALL co-culture model we created the protocol provided in Chapter 2 for
the establishment, maintenance, and recovery of ALL cells in an in vitro model to
provide us a source of leukemic cells that would represent the most treatment refractory
component of the disease (PD cells)12. One important finding from this study was that
for this system to provide accurate and reproducible results, the cultures had to be
maintained using a strict feeding and passage (culturing) schedule in which co-cultures
were fed at 4 day intervals and transferred to new BMSC or HOB layers every 12
days12. To enhance the usefulness of this model, we combined it with the previously
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described gel type 10 cross-linked dextran (G10) particle columns14, to provide an
efficient method for separation of the ALL cells from the adherent monolayers. The
ability to generate and separate the three distinct ALL populations allowed us to
address questions related to potential differences in the phenotypes of the ALL
populations based on their spatial location in relation to BMSC or HOB. It is well
established that one critical consequence of leukemic cells interacting with BMSCs and
HOBs, both in vitro and in vivo, is an increase in chemotherapy resistance12,13,15–21. We
found that ALL cells of the PD population were the most chemotherapy resistant relative
to the other populations, noted above. This important observation lead us to further
characterize the PD population to determine the functional consequences that result
from this intimate relationship between the ALL cells and the BMM in this in vitro model
of treatment resistant ALL.
Based on the observation that PD ALL cells are the most chemotherapy resistant
population in our co-culture model, we sought to investigate potential phenotypic
changes in the PD population that contribute to chemotherapy resistance. Furthermore,
we evaluated whether PD cells are unique based on intrinsic factors of the leukemic
cells or if the protection is mediated by the specific interactions with the bone marrow
niche cells. Consistent with the observations described in Chapter 2, we found that a
variety of ALL cell lines interact with BMSC and HOB in co-culture and readily form
three populations (S, PB, and PD), as highlighted in Chapter 313. Additionally, we
investigated whether the three individual groups of ALL cells had specific affinity for the
location from which they were isolated. This is important as ALL disease is known to be
very heterogeneous, often leading to generation of subclones which are chemotherapy
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resistant6. However, we found through the use of labeling and tracking experiments that
tumor cells recovered from any spatial location (S, PB or PD) were able to reestablish
the other two subpopulations when placed onto a new BMSC or HOB monolayer 13.
These findings show that ALL cells in our co-culture model behave in a dynamic
manner, readily moving in and out of different niches within the culture. This provides
the theoretical opportunity of forcing tumor cells out of resistant niches or directly
targeting cells in the resistant niche (modeled by the PD), to render them more
responsive to treatment interventions. Interestingly, while this co-culture model is
admittedly a reductionist view of the BMM, it does somewhat recapitulate normal
marrow dynamics. Both normal and malignant hematopoietic cells have been shown in
vivo to migrate between different marrow niches22–24. Movement between the different
niches is thought to be one mechanism by which HSCs and progenitor cells are either
maintained, cued to proliferate, or stimulated to differentiate 23. We speculate that while
the migration in our in vitro system is simple in comparison to that in the BMM, our
model may provide a tool to study signaling cues that trigger ALL cells to egress from
the niche spaces. This would be of therapeutic use as mobilization of ALL cells from the
protected niche may render them more susceptible to chemotherapy intervention.
We further expanded on the observation that PD ALL cells have increased
chemotherapy resistance, when compared to their co-cultured counterparts (S and PB
tumor cells) through experimentation with increased numbers of ALL cell lines and
cytotoxic agents. In Chapter 3, we describe our observations when ALL cells in media
alone and in our co-culture model are exposed to three commonly used chemotherapy
drugs, Ara-C, methotrexate, and vincristine13. We found that in every treatment
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condition, across multiple tumor cell lines, PD ALL cells had little to no decrease in
viability relative to untreated controls, and had significantly increased viability compared
to cells cultured in media alone. Of concern was whether the increase in PD cell survival
was related to interactions specific to BMSC/HOB, or whether this was the result of a
generic phenomenon that would be observed related to migration and protection
beneath any adherent monolayer. Additionally, it is known that uptake of chemotherapy
drugs by the tumor cell greatly effects the efficacy of the treatment20,25. To address this
we established co-cultures using variety of non-bone marrow derived stromal cells.
While the ALL cells co-cultured with these non-bone marrow derived stromal cells did
form a PD population, they were not protected from chemotherapy exposure. Moreover,
our laboratory has previously shown that ALL cells in co-culture have no difference in
chemotherapy uptake relative to tumor cells grown in media alone26. Together, these
results suggest that interactions or cues specific to the BMM are responsible for
signaling that converges on ALL resistance to chemotherapy in our co-culture model.
As described in Chapter 1, the BMM impacts the hematopoietic cell phenotype in
a variety ways. One critical function of the BMM is to prevent stem cell exhaustion
through regulatory signaling that promotes quiescence22,27,28. Due to similarities
between ALL cells and their normal hematopoietic counterparts, ALL cells are able to
hijack the normal niches and benefit from their protective signaling29. A significant
instance of this is the ability of ALL cells to localize to quiescence promoting niches and
as a result evade chemotherapy intervention. For example, expression of osteopontin in
the osteoblastic niche has been shown to maintain HSCs in a quiescent state 30,31.
Likewise, Boyerinas et al. found that ALL cells localized to the endosteum and
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interacted with osteopontin resulting in a quiescent and drug resistant phenotype15.
Chemotherapy resistance as a result of quiescence is not specific to ALL and it is well
established that tumor cells in a dormant or quiescent state are responsible for resistant
disease and relapse events in a variety of malignancies25,32. As such, we sought to
investigate whether the chemotherapy resistant PD ALL population had an altered cell
cycle and proliferation profile. We found that PD cells are characterized by an increased
percentage of cells in G0/G1 and decreased S phase percentage compared to cells in
media alone13. Additionally, we observed that the PD population had an increase in cells
in G0 phase, along with a reduction in KI-67 staining relative to media alone controls13.
These findings suggest that the BMM is promoting a quiescent ALL phenotype, which
based on previous works is likely contributing to the chemotherapy resistance we
observed in this population. Again, this model’s ability to mimic well established
microenvironment paradigms that promote resistant disease further validates its
usefulness as a tool to model chemotherapy resistant disease in vitro. As we show in
Chapter 4, it can be used as a platform to investigate the interactions that lead to
quiescence in ALL cells and inform strategies to disrupt this resistant phenotype.
Interestingly, in addition to having a quiescent phenotype, we found that PD ALL
cells have an altered metabolic status compared to ALL cells in media alone culture
conditions. PD ALL cells appear to have increased glycolytic activity and a reduced
level of oxidative phosphorylation. Consistent with the observed increase in glycolysis,
we observed increased protein abundance in hexokinase 1 and 2, which are the first
rate limiting enzymes of the glycolytic pathway13,33. Additionally, metabolomic analysis
via mass spectrometry revealed that ALL cells in co-culture have a different metabolite
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profile compared to media alone ALL cells13. These findings are reminiscent of the
classically described Warburg effect, where tumor cells are characterized by a
preferential increase in glucose metabolism over oxidative phosphorylation 34. Increased
glycolysis and altered cellular metabolism have been associated with chemotherapy
resistance through a variety of proposed mechanisms35. Future work will be needed to
determine to what extent the observed increase in glycolytic activity has on
chemotherapy resistance in the PD ALL cells. Moreover, we speculate that in addition to
the potential for increased resistance, the increase in glycolysis might provide PD ALL
cells with the ability to increase biomass, “priming” the cells for proliferation when
released from the microenvironment. This speculation is based on the ability of
glycolysis intermediates to be used in fatty acid, amino acid, and nucleotide synthesis 36.
A greater understanding of how this increase in glycolysis impacts ALL cell resistance
and potential contributions to biomass production may provide strategies to target ALL
cells that have altered metabolic profiles.
The overall goal of studies presented in Chapters 2 and 3 was to establish and
characterize an in vitro model, which in part recapitulates dynamic interactions between
ALL cells and the BMM that promote ALL resistance. While it is appreciated that murine
models will remain the standard for investigation of therapeutic agents, our in vitro
model provides a relatively fast and cost effective method to model resistant ALL. While
we do not suggest that the PD population of tumor cells in our model are identical to the
cells that initiate relapse of disease in patients, they are a treatment refractory,
quiescent population that provides a very valuable tool for investigation of critical anti-
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apoptotic and cell cycle regulatory pathways. As such, utilizing this system, we
investigated whether interaction with BMM influences ALL expression of BCL6.
The goal of the study presented in Chapter 4 was to investigate a fundamental
gap in knowledge focused on whether BCL6 abundance in ALL cells was affected
through interaction with the BMM and the consequence of BCL6 levels in terms of tumor
cell phenotype. BCL6 is a proto-oncogene that was discovered and classically
described in germinal center biology and cases of DLBCL37–40. BCL6 has been shown
to promote proliferation in a variety of contexts through the regulation of cell cycle
regulating proteins such as p27, p21, BLIMP-1, and by rendering cells unresponsive to
anti-proliferative signals arising from the p19 (ARF)-p53 pathway40–43. Consistently, high
BCL6 protein expression is associated with rapidly proliferating germinal center B-cells44
and has been shown to positively correlate with proliferation associated protein Ki-6745.
Conversely, BCL6 has also been presented as a mediator of cell cycle repression and
senescence. Nahar et al. demonstrated that BCL6 expression could result in repression
of MYC leading to cell cycle arrest and quiescence46. Similarly, Ranuncolo et al. found
that BCL6 could trigger growth arrest and senescence through a p53 dependent
pathway47. These findings illustrate the complexity and diversity of BCL6 regulation.
They also highlight the need for studies that explore BCL6 functions through context
specific experimentation, with focus on normal and tumor microenvironment influences
that may affect BCL6 driven phenotypes. To this end, this study explored the role BMM
derived cells have on BCL6 protein abundance in ALL cells. Utilizing our in vitro coculture model, we found BMSC and HOB interaction results in decreased BCL6 levels in
ALL cells48. Furthermore, we show that BCL6 abundance is impacted to the greatest
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extent in the chemotherapy resistant PD ALL cells48. These findings were striking
because elevated BCL6 expression in CML and ALL cells has been shown to promote
chemotherapy resistance through tolerance to DNA damaging stress via repression of
p53 signaling49,50. This apparent ambiguity lead us to investigate other tumor strategies,
which can lead to a chemotherapy resistance and that may be influenced by BCL6
downregulation. As described in the Chapter 3 study, we found that the resistant PD
population was characterized by a quiescent phenotype13. Consistent with this
observation and the known function of BCL6 as a driver of proliferation, we found that
inhibition of BCL6 in our hands lead to diminished proliferation and blunted cell cycle
progression in ALL cells, with overexpression leading to the reverse phenotype 48.
Additionally, we discovered that cyclin D3 protein abundance was regulated
downstream of BCL6 inhibition or overexpression48. These findings are significant as
cyclin D3 has been shown to be a key regulator of B-cell progression through the G1
phase of cell cycle51–53. Together, these findings point to microenvironment
downregulation of BCL6 as a mechanism to blunt ALL cell cycle progression and
subsequent chemotherapy resistance through induction of a quiescent phenotype.
Due to the fact that many chemotherapy regimens target dividing cells, standard
treatments are often less effective against quiescent tumor populations25,32. Based on
this premise, one goal of this study was to investigate strategies to improve the efficacy
of chemotherapy treatments against quiescent ALL cells in the BMM. With the findings
that PD ALL cells have a quiescent phenotype, which is in part mediated through BMSC
and HOB driven reduction of BCL6 protein abundance in ALL cells, we sought to
determine whether combination strategies aimed at chronically increasing BCL6 would
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sensitize ALL cells to chemotherapy. To this end, we found that chronic constitutive
BCL6 expression lead to increased sensitivity of ALL cells to chemotherapy exposure48.
Additionally, we investigated MG132 and caffeine exposure as an approach to
chemically modulate BCL6 expression in ALL cells. Both MG132 and caffeine have
been shown to stabilize BCL6 expression through repression of pathways (proteasome
and ATM/ATR inhibition respectively) that lead to proteasomal mediated degradation of
BCL648,54. Consistent with these observations, we found that exposure to MG132 or
caffeine increased protein abundance of BCL6 in ALL cells, and that both drugs were
able to increase BCL6 expression in target PD ALL cells48. Employing these two drugs
to chronically increase BCL6 in the PD population, we discovered that combination
treatment with chemotherapy resulted in sensitization of PD ALL cell compared to
chemotherapy only treated groups48. While it is appreciated that neither MG132 or
caffeine specifically target BCL6, they both represent a tool to sensitize ALL resistant
ALL cells to chemotherapy, which is in part mediated through their influence on BCL6
expression. Based on these encouraging in vitro results, we investigated both MG132
and caffeine as sensitization agents in a murine model of ALL disease. In these
studies, we found that caffeine treatment in combination with Ara-C significantly
increased the event free survival of mice compared to treatment with chemotherapy
alone48. Again, while caffeine is not likely acting through BCL6 modulation exclusively, it
does appear to be useful in sensitizing ALL cells to chemotherapy. These findings in
concert with the results of the in vitro studies supports further investigation of BCL6
modulation and caffeine treatment as potential approaches to target resistant ALL
disease. We speculate that caffeine treatment might be a beneficial addition to
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consolidation regimens to potentially bring quiescent residual tumor cells into cycle so
that they may be more effectively targeted by chemotherapy. Overall, the findings of the
study presented in Chapter 4 begin to address the lack of understanding of how the
BMM influences ALL expression of BCL6. We hope that this study will provide a
springboard for further investigations into context specific BMM regulation of BCL6 and
inform potential treatment strategies targeting resistance in the marrow niche.
The studies presented herein further advance the field of ALL research through
establishment of an in vitro co-culture model in which BMM supported and
chemotherapy resistant disease can be further investigated. To our knowledge, this
work represents the first time that BMM influence on ALL BCL6 protein abundance has
been investigated. The presented studies show the progression from establishment of
the in vitro model, to its use in the investigation of BCL6 as a mechanism of
chemotherapy resistance in ALL cells, and finally its ability to provide a platform for
investigations which informed the treatment strategies used in our in vivo murine
studies. We envision that future work will be able to build upon this research in a variety
of ways. For example, the observation that the PD ALL cells have increased glycolytic
activity will require additional investigation to determine the impact of this altered
metabolism on resistant disease and potential for relapse. Additionally, it will be critical
to expand on the findings surrounding BCL6 modulation downstream of the BMM. A
mechanistic insight into how this modulation is mediated may provide additional targets
for sensitization strategies against refractory ALL. Moreover, it will be important to gain
a better understanding of the cellular context in which BCL6 is altered in ALL cells, as
changes in pathways such as p53, ATM/ATR, PI3K, and BCL family proteins can
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dramatically affect BCL6’s regulation of cell phenotype as highlighted above. Finally, the
observation that caffeine sensitizes ALL cells to chemotherapy warrants further
investigation. Caffeine’s long history of safe use in humans and our observation of its
use as a sensitizing agent give it the potential to become an attractive addition to the
current treatment regimens. In this way, we are hopeful that this work will fit into the
long history of successful additions to the combination treatment advances that first
began to improve outcomes in ALL patients of the corporative children’s groups of the
1950’s. Finally, we are optimistic that this work, as well as those similarly investigating
strategies to disrupt bone marrow microenvironment protection of ALL, will provide the
final brick in the long road to curing this once uniformly fatal disease.
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